CN111808089A - Preparation method of drug eprogliflozin for treating diabetes or derivative thereof - Google Patents

Preparation method of drug eprogliflozin for treating diabetes or derivative thereof Download PDF

Info

Publication number
CN111808089A
CN111808089A CN201910287224.8A CN201910287224A CN111808089A CN 111808089 A CN111808089 A CN 111808089A CN 201910287224 A CN201910287224 A CN 201910287224A CN 111808089 A CN111808089 A CN 111808089A
Authority
CN
China
Prior art keywords
compound
nmr
cdcl
alpha
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910287224.8A
Other languages
Chinese (zh)
Other versions
CN111808089B (en
Inventor
孙洪宝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
West China Hospital of Sichuan University
Original Assignee
West China Hospital of Sichuan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West China Hospital of Sichuan University filed Critical West China Hospital of Sichuan University
Priority to CN201910287224.8A priority Critical patent/CN111808089B/en
Publication of CN111808089A publication Critical patent/CN111808089A/en
Application granted granted Critical
Publication of CN111808089B publication Critical patent/CN111808089B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides a preparation method of drug eprogliflozin for treating diabetes or a derivative thereof. The invention utilizes alpha-O-alkenyl sulfone as electrophilic reagent to carry out Suzuki-Miyaura coupling reaction, the reaction raw material alpha-O-alkenyl sulfone has simple preparation and stable structure, and can overcome the defects of instability, difficult preparation and the like existing when organic halide and sulfonic acid are used as electrophilic reagent of Suzuki-Miyaura coupling reaction. Meanwhile, the reaction conditions of the reaction are mild, the heterocyclic ring and various functional groups can be compatible, the yield is high, and the large-scale process production can be realized. Meanwhile, the invention utilizes alpha-O-alkenyl sulfone as an electrophilic reagent to carry out Suzuki-Miyaura coupling reaction, can generate aryl glycoside and open-chain alkenyl ether with high yield, can also prepare type II diabetes drugs of eggliflozin and 2-deoxyeggliflozin, and has wide application.

Description

Preparation method of drug eprogliflozin for treating diabetes or derivative thereof
Technical Field
The invention belongs to the field of chemistry, and particularly relates to a preparation method of a drug for treating diabetes mellitus, namely, epropanal or a derivative thereof.
Background
Suzuki-Miyaura coupling reaction, which is called Suzuki-Miyaura coupling reaction, has irreplaceable positions in organic synthesis and pharmaceutical chemistry, and can realize the construction of carbon-carbon bonds and synthesize a large amount of molecular frameworks. The obtained and stable organic boron reagent is used as an affinity reagent and plays a great role in the reactions. The most commonly used electrophilic reagents in the Suzuki-Miyaura coupling reaction are organic halides and sulfonic acid, and the compounds have the defects of low reactivity, instability, difficult preparation and the like, so that the development of alternative electrophilic reagents is very important.
Sulfones represent one of the basic functional groups in chemistry. The versatility and general stability of sulfones makes them important intermediates in many complex product synthesis schemes. However, the use of sulfones as electrophiles in cross-coupling reactions is relatively rare compared to organic halides or sulfonates, mainly for the following reasons: one is that the oxidative insertion of the less polarized C — SO2R bond is considered more difficult; second, sulfones contain two C-SO2 bonds, which present selectivity problems during the oxidative insertion step; thirdly, during the oxidation insertion, the generated sulfinate (RSO2-) is easy to remove sulfur dioxide to obtain R negative ions, and then a nucleophilic reagent rather than an electrophilic reagent enters the catalytic cycle again, so that the purpose is difficult to achieve. For example, the Yorimitsu group reports intramolecular desulfurization coupling of diaryl sulfones to yield diaryl groups.
Despite the above challenges, great progress has been made in using sulfones as electrophiles in cross-coupling. Interestingly, although vinyl or aryl sulfones have a longer history of use as C (sp2) electrophiles, this has been dormant since pioneering studies by the Wenker and Julia topics. Most reported methods use grignard reagents as nucleophiles, which greatly limits their synthetic utility.
While the eprograzin or the derivative thereof is a medicine with better treatment effect on the type 2 diabetes mellitus, if a novel method for treating the eprograzin or the derivative thereof can be provided, the cost is low, and the yield is high, so that the method is good news for patients with the diabetes mellitus.
Disclosure of Invention
In order to solve the problems, the invention provides a preparation method of an eprost drug for treating diabetes or a derivative thereof.
The invention provides a preparation method of drug of eggliflozin for treating diabetes or a derivative thereof, which comprises the following steps:
(1) reacting alpha-O-alkenyl sulfone, an organic boron reagent, a ligand, alkali and a catalyst in a solvent to obtain a compound I;
(2) reducing and substituting the compound I to obtain a coarse product of the epropanal; or the compound I is reduced to obtain a crude product of the epropanal derivative;
(3) purifying the crude product of the eprost or the crude product of the eprost derivative to obtain the eprost or the eprost derivative;
wherein the structural formula of the alpha-O-alkenyl sulfone is shown as a formula II:
Figure BDA0002023477080000011
in the formula II, the reaction mixture is shown in the formula II,
n is an integer of 0 to 4;
R1independently selected from substituted or unsubstituted C1～C6Alkyl, -OR3Or any two R1Connecting to form a substituted or unsubstituted 3-to 6-membered heterocyclic group; the substituent of the alkyl is halogen, nitryl, amino, hydroxyl, cyano-OR3(ii) a The substituent of the heterocyclic group is C1～C6An alkyl group;
R2selected from substituted or unsubstituted aryl, substituted or unsubstituted 3-8 membered heterocyclic group; the substituent of the aryl or the heterocyclic group is C1～C6Alkyl, halogen, C1～C6Alkoxy, cyano, nitro, amino, hydroxy;
R3selected from benzyl, TBS group, TIPS group, substituted or unsubstituted 3-6 member heterocyclic group; the substituent of the heterocyclic group is substituted or unsubstituted C1～C6Alkyl, -OR4(ii) a The substituent of the alkyl is halogen, hydroxyl, -OR4；
R4Selected from benzyl, TBS groups, TIPS groups;
the organoboron reagent is
Figure BDA0002023477080000021
The structural formula of the compound I is
Figure BDA0002023477080000022
In the compound I, the reaction mixture is subjected to reaction,
n and R1The same as the alpha-O-alkenyl sulfone shown in the formula II.
Further, in the step (1), the molar ratio of the alpha-O-alkenyl sulfone to the organoboron reagent to the ligand to the base to the catalyst in the coupling reaction is 1: 1-5: 0.1-0.5: 1-5: 0.05-0.25; the molar volume ratio of the alpha-O-alkenyl sulfone to the solvent is 0.1-10: 1 (mol/L);
preferably, the mol ratio of the alpha-O-alkenyl sulfone to the organoboron reagent to the ligand to the base to the catalyst in the coupling reaction is 1: 1.5-2: 0.1-0.2: 2: 0.1; the molar volume ratio of the alpha-O-alkenyl sulfone to the solvent is 0.1-0.. 2:1 (mol/L);
more preferably, the molar ratio of the alpha-O-alkenyl sulfone, the organoboron reagent, the ligand, the base and the catalyst in the coupling reaction is 1:2:0.2:2: 0.1; the molar volume ratio of the alpha-O-alkenyl sulfone to the solvent is 0.2:1 (mol/L).
Further, the air conditioner is provided with a fan,
in the formula II, the reaction mixture is shown in the formula II,
n is an integer of 2-3;
R1independently selected from substituted OR unsubstituted methyl, -OR3Or any two R1To form a substituted 6-membered heterocyclic group; the substituent of the methyl is-OR3(ii) a The substituent of the heterocyclic group is C4An alkyl group;
R2selected from substituted or unsubstituted aryl, substituted or unsubstituted 6-membered heterocyclyl; the substituent of the aryl or the heterocyclic group is C1～C3Alkyl, halogen;
R3selected from benzyl, TBS groups, TIPS groups, substituted 6-membered heterocyclic groups; the substituent of the heterocyclic group is substituted methyl alkyl, -OR4(ii) a The substituent of the alkyl is-OR4；
R4Is selected from benzyl;
preferably, the α -O-alkenyl sulfone is of one of the following structural formulae:
Figure BDA0002023477080000023
Figure BDA0002023477080000031
more preferably, the α -O-alkenyl sulfone is of one of the following structural formulae:
Figure BDA0002023477080000032
further, in step (1), the ligand is selected from Ph3P or Cy3P·HBF4(ii) a The alkali is selected from KOH or NaOH; the catalyst is a Ni-containing catalyst; the solvent is tetrahydrofuran or tert-butyl alcohol;
preferably, in step (1), the ligand is Cy3P·HBF4(ii) a The alkali is KOH; the catalyst is Ni (COD)2(ii) a The solvent is tetrahydrofuran.
Further, in the step (1), the reaction temperature is 60-80 ℃; the reaction time is 8-16 h; preferably, the reaction time is 12-16 h.
Further, in the step (2), the compound I is reduced and substituted to obtain a crude product of the isegelizin, wherein the compound I is reduced to be dissolved in a solvent, cooled to 0 ℃, slowly added with a reducing agent and stirred for 10-15 hours; the substitution is that 3% H is added into the reduced product2O2Then adding 3M NaOH aqueous solution, and stirring at room temperature for 20-25 h to obtain the aqueous solution; after the substitution, purifying the substituted product;
wherein the molar ratio of the compound I to the reducing agent is 1-5; the molar volume ratio of the compound I to the solvent is 0.1: 1-5 (mol/L); compound I and 3% H2O2The molar volume ratio of (a) is 0.1: 1-5 (mol/L); the molar volume ratio of the compound I to the NaOH aqueous solution is 0.1: 1-5 (mol/L);
preferably, in the step (2), the molar ratio of the compound I to the reducing agent is 1-3; mols of Compound I with solventThe molar volume ratio is 0.1:2 (mol/L); compound I and 3% H2O2The molar volume ratio of (a) to (b) is 0.1:3 (mol/L); the molar volume ratio of the compound I to the aqueous NaOH solution was 0.1:3 (mol/L).
Further, in the step (2), the compound I is reduced and substituted to obtain the ipragliflozin, the reduced compound I is dissolved in tetrahydrofuran, the temperature is cooled to 0 ℃, borane-tetrahydrofuran is slowly added, and the mixture is stirred for 12 hours; the substitution is that 30% H is added into the reduced product2O2Then adding 3M NaOH aqueous solution, and stirring at room temperature for 24 h; diluting the substituted product with dichloromethane, washing, drying an organic layer, filtering, and distilling under reduced pressure to obtain the product after purification;
preferably, in step (2), the purification is performed by diluting the substituted product with dichloromethane, and then sequentially using 20% NaHSO3Saturated NH4Washing with Cl, water and saturated brine, and washing the organic layer with anhydrous Na2SO4Drying, filtering, and distilling under reduced pressure.
Further, in the step (2), after the compound I is reduced, the crude product of the ipragliflozin derivative is obtained, the reduced compound I is dissolved in a solvent, and the mixture is stirred and reacts for 20-30 hours in a hydrogen environment under the action of a catalyst; after the reduction, purifying the reduced product;
wherein the mass-volume ratio of the compound I to the solvent is 1: 500-550 (w/v); the mass ratio of the compound I to the catalyst is 1: 0.2-0.6;
preferably, in the step (2), the mass-to-volume ratio of the compound I to the solvent is 1: 527-528 (w/v); the mass ratio of the compound I to the catalyst is 1: 0.4-0.5.
Further, in the step (2), the solvent consists of ethyl acetate and methanol in a volume ratio of 5: 1; the catalyst is 10% Pd/C; the stirring reaction time is 24 hours; the purification is carried out by filtering with diatomite and reduced pressure distillation.
Further, in the step (3), the purification is to dissolve the crude product in tetrahydrofuran, add tetrabutylammonium fluoride, stir at room temperature for 2h, perform reduced pressure distillation and column chromatography separation.
Further, the structural formula of the epropanal or the epropanal derivative is shown as a formula III:
Figure BDA0002023477080000041
preferably, the structure formula of the epropane or the epropane derivative is shown as the formula IIIA:
Figure BDA0002023477080000042
more preferably, the structure of the eprogliflozin or eproflozin derivative is as follows:
Figure BDA0002023477080000043
the compounds and derivatives provided in the present invention may be named according to the IUPAC (international union of pure and applied chemistry) or CAS (chemical abstracts service, Columbus, OH) naming system.
Definitions of terms used in connection with the present invention: the initial definitions provided herein for a group or term apply to that group or term throughout the specification unless otherwise indicated; for terms not specifically defined herein, the meanings that would be given to them by a person skilled in the art are to be given in light of the disclosure and the context.
"substituted" means that a hydrogen atom in a molecule is replaced by a different atom or molecule.
The structures of the compounds in the invention are all structures capable of stably existing.
Substituent groups of the invention "-C (O) R7The structural formula is
Figure BDA0002023477080000044
Substituent group' -OR of the invention2The structural formula is
Figure BDA0002023477080000045
Substituent group "-NR" of the present invention5R6The structural formula is
Figure BDA0002023477080000046
The minimum and maximum carbon atom contents of the hydrocarbon groups in the present invention are indicated by prefixes, e.g. prefix (C)a～Cb) Alkyl means any alkyl group containing from "a" to "b" carbon atoms. Thus, for example, C1～C8The alkyl refers to a straight chain or branched chain alkyl containing 1-8 carbon atoms; c1～C8The alkoxy group means an alkoxy group having 1 to 8 carbon atoms.
In the present invention, the 3-to 6-membered heterocyclic group is a saturated or unsaturated monocyclic heterocyclic group having 3 to 6 atoms, and the heterocyclic group carries at least one selected from O, S or a substituted nitrogen atom and a silicon atom.
In the present invention, halogen is fluorine, chlorine, bromine or iodine.
In the invention, the benzo 3-6-membered heterocyclic group refers to a benzene ring and a 3-6-membered heterocyclic group.
In the present invention, the abbreviations are those commonly used in the chemical arts, such as: TBS group is tert-butyldimethyl; the TIPS group is triisopropyl silicon group; bn is benzyl;tbu is butyl; ph is an aryl group; me is methyl; et is ethyl; boc is tert-butyloxycarbonyl; tol is tolyl.
The alpha-O alkenyl sulfone in the invention means that an oxygen is connected to the alpha position of the alkenyl sulfone, and the structural general formula is
Figure BDA0002023477080000051
Wherein R is1Is a substituent on the ring, n is the number of the substituent, R2Is a substituent on the sulfone group.
The invention takes the alpha-O-alkenyl sulfone as the electrophilic reagent, can effectively carry out the Suzuki-Miyaura coupling reaction, does not have a plurality of problems existing in the Suzuki-Miyaura coupling reaction in which the sulfone participates, has simple preparation and stable structure of the reaction raw material alpha-O-alkenyl sulfone, and can overcome the defects of instability, difficult preparation and the like existing when the organic halide and the sulfonic acid are used as the electrophilic reagent of the Suzuki-Miyaura coupling reaction. Meanwhile, the reaction conditions of the reaction are mild, the heterocyclic ring and various functional groups can be compatible, the yield is high, and the large-scale process production can be realized. Meanwhile, the invention utilizes alpha-O-alkenyl sulfone as an electrophilic reagent to carry out Suzuki-Miyaura coupling reaction, can generate aryl glycoside and open-chain alkenyl ether with high yield, can also prepare type II diabetes drugs of eggliflozin and 2-deoxyeggliflozin, and has wide application.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Detailed Description
The raw materials and equipment used in the embodiment of the present invention are known products and obtained by purchasing commercially available products.
Example 1 preparation of an electrophile of the invention alpha-O-alkenylsulfone
1. Synthesis of 1-phenylsulfonyl-3, 4, 6-tribenzyloxy-D-glucal (8a)
Figure BDA0002023477080000052
M-chloroperoxybenzoic acid (mCPBA, 2.5g,11.26mmol,2.2equiv) was added in portions to a solution of SI-1(3.24g,5.12mmol,1.0equiv) in Dichloromethane (DCM) at 0 ℃, stirred at room temperature for 2 hours, and then filtered through celite. Adding saturated NaHCO into the filtrate3And Na2S2O3Stirring the solution for 10min with dichloromethaneExtracting and distilling under reduced pressure. Subsequent purification by chromatography (petroleum ether/ethyl acetate 4:1) gave SI-2(2.65g,3.99mmol) in 78% yield.
Adding SI-2(2.65g,3.99mmol,1.0equiv) in N2Dissolved in tetrahydrofuran (THF,25mL) under the protection conditions, stirred at 0 ℃ and then lithium bistrimethylsilylamide (LiHMDS,3.0mL, in n-hexane solution, at a concentration of 2.0M,1.5equiv) was added dropwise thereto. Point plate monitoring, use saturated NH after reaction4The reaction was quenched with Cl solution, extracted with ethyl acetate and then distilled under reduced pressure. Purification on silica gel (petroleum ether/ethyl acetate 8:1) gave 8a (2.1g,3.79mmol) as a white solid in 95% yield.1H NMR(CDCl3,400MHz):7.95(d,J＝7.7Hz,2H),7.57(t,J＝7.5Hz,1H),7.46(t,J＝7.7Hz,2H),7.36–7.24(m,11H),7.23–7.14(m,4H),6.22(d,J＝3.0Hz,1H),4.73(d,J＝11.3Hz,1H),4.68(d,J＝11.6Hz,1H),4.60(d,J＝11.3Hz,1H),4.56(d,J＝11.6Hz,1H),4.35(d,J＝12.0Hz,1H),4.31(d,J＝12.0Hz,1H),4.26(dd,J＝6.1,3.0Hz,1H),4.19(ddd,J＝8.1,4.6,3.1Hz,1H),3.85(dd,J＝8.1,6.0Hz,1H),3.71(dd,J＝11.5,4.6Hz,1H),and 3.66(dd,J＝11.5,3.1Hz,1H).13C NMR(CDCl3,101MHz):152.61,138.07,138.04,137.81,137.49,133.96,129.11,128.73,128.65,128.51,128.39,128.12,127.97,127.94,127.68,127.53,105.80,79.89,74.87,73.86,73.41,71.45,and 67.61.IR(thin film,cm-1):3030,2866,1647,1448,1324,1160,1069,1026,734,725,696,685,and613cm-1.HRMS(DART-TOF)calculated for C33H32NaO6S+[M+Na]+m/z 579.1812, found579.1821 melting point 75.5-79.6 ℃.
2. Synthesis of 1- (4-trifluoromethylphenylsulfonyl) -3,4, 6-tribenzyloxy-D-glucal (8b)
Figure BDA0002023477080000061
SI-3(2.34g,6.0mmol,1.0equiv) and 4- (trifluoromethyl) thiophenol (1.07g,6.0mmol,1.0equiv) were dissolved in 15ml dichloromethane and BF was added slowly under nitrogen at 0 deg.C3·Et2O(2.34g,6.0mmol,1.0equiv)。It was then stirred at room temperature for 8h with saturated NH4Quenching with Cl solution, washing with 0.3N NaOH solution, anhydrous Na2SO4Drying, distillation under reduced pressure, and silica gel chromatography (petroleum ether/ethyl acetate 4:1) gave the product (1.37g,2.7mmol) in 45% yield.
In N2The product from the previous step (1.37g,2.7mmol,1.0equiv) was dissolved in methanol under protective conditions, NaOMe (58mg,1.08mmol,0.4equiv) was added and stirred at room temperature for 2h, and distilled under reduced pressure. The spin-dried mixed system was dissolved in N, N-dimethylformamide (DMF,18mL), N2Adding NaH (864mg,21.6mmol,8.0equiv dispersed in mineral oil at 60% in portions at 0 ℃ under the protection condition), stirring for 15min, adding BnBr (3.69g,21.6mmol,8.0equiv) dropwise within 10min, moving to room temperature, stirring for 15h, pouring the reaction liquid into ice water for quenching, extracting with ethyl acetate (20mL x 3), and extracting with anhydrous Na2SO4Drying, vacuum distillation, silica gel column purification (petroleum ether/ethyl acetate 10:1) gave SI-4(1.61g,2.3mmol) in 85% yield.
SI-4(1.61g,2.3mmol,1equiv) was dissolved in 15ml DCM, m-chloroperoxybenzoic acid (1.1g,5.06mmol,2.2equiv) was added portionwise at 0 deg.C, stirred at room temperature for 2h, filtered, and saturated NaHCO3The reaction was quenched in solution and Na was added2S2O3The solution was stirred for 10 min. Then, the organic layer was distilled under reduced pressure, and the crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate ═ 5:1) to obtain a product (1.43g,1.9mmol) with a yield of 85%.
The product obtained in the previous step was dissolved in 20ml THF at-78 ℃ and N2Lithium diisopropylamide (LDA,1.8mL, dissolved in n-hexane, 2M,1.5equiv) was added dropwise under protection, monitored by TLC plate at-78 deg.C, saturated NH4The reaction was quenched with Cl. The reaction was allowed to warm to room temperature, extracted with ethyl acetate, and the organic layer was distilled under reduced pressure and purified by silica gel chromatography (petroleum ether/ethyl acetate 7:1) to give light yellow foamy solid 8b (1.16g,1.9mmol) in 82% yield.1H NMR(CDCl3,400MHz):8.06(d,J＝8.2Hz,2H),7.69(d,J＝8.2Hz,2H),7.35–7.27(m,11H),7.22–7.16(m,4H),6.23(d,J＝3.1Hz,1H),4.73(d,J＝11.3Hz,1H),4.68(d,J＝11.6Hz,1H),4.60(d,J＝11.6Hz,1H),4.57(d,J＝11.6Hz,1H),4.39(d,J＝11.9Hz,1H),4.35(d,J＝11.9Hz,1H),4.26(dd,J＝5.9,3.1Hz,1H),4.22(ddd,J＝7.9,4.7,3.1Hz,1H),3.85(dd,J＝8.0,5.9Hz,1H),3.72(dd,J＝11.4,4.8Hz,1H),and 3.67(dd,J＝11.4,3.2Hz,1H).13C NMR(CDCl3,101MHz):151.91,141.79,137.84,137.69,137.38,135.54(q,J＝33.1Hz),129.27,128.70,128.56,128.49,128.21,128.07,127.99,127.98,127.87,127.56,126.24(q,J＝3.7Hz),123.24(q,J＝273.7Hz),106.93,79.93,74.63,73.88,73.46,73.29,71.60,and 67.56.19F NMR(CDCl3,376MHz):–63.18.IR(thin film,cm-1):3029,3006,2989,2866,1320,1275,1261,1166,1131,1105,1060,1015,764,749,713,696,and 605cm-1.HRMS(DART-TOF)calculated for C34H31F3NaO6S+[M+Na]+m/z 647.1686,found 647.1695.
3. Synthesis of 1-phenylsulfonyl-3, 4, 6-tri-tert-butyldimethylsilyloxy-D-glucal (15a)
Figure BDA0002023477080000071
SI-3(2.34g,6.0mmol,1.0equiv) and thiophenol (792mg,7.2mmol,1.2equiv) were dissolved in 15ml dichloromethane, N2And at 0 deg.C, adding BF slowly3·Et2O (1.28g,9.0mmol,1.5equiv), stirred at room temperature for 8h, saturated NH4The Cl solution was quenched and washed with 0.3N aqueous NaOH. The organic layer was washed with anhydrous Na2SO4Drying, distillation under reduced pressure, and purification on silica gel (petroleum ether/ethyl acetate 4:1) gave the product (2.73g,5.4mmol, yield 90%).
In N2The product obtained in the previous step (2.73g,5.4mmol,1.0equiv) was dissolved in methanol under protective conditions, NaOMe (116mg,2.16mmol,0.4equiv) was added and stirred at room temperature for 2h, and distilled under reduced pressure. The resulting material was then dissolved in dichloromethane (30mL), N2And at 0 deg.C, 2, 6-lutidine (5.78g,54mmol,10.0equiv) and tert-butyldimethylsilyltrisidine were addedFluoromethanesulfonate (TBSOTf, 1.16g,43mmol,8.0equiv), stirred at room temperature for 8h, diluted with dichloromethane, extracted with saturated brine and dichloromethane (20mL x 3), anhydrous Na2SO4After drying, distillation under reduced pressure and silica gel chromatography (15: 1 petroleum ether/ethyl acetate) gave the TBS protected product SI-5(3.74g,5.1mmol, 95% yield).
Dissolving SI-5(3.74g,5.1mmol,1equiv) in 30ml dichloromethane, adding m-chloroperoxybenzoic acid (mCPBA, 2.42g,11.2mmol,2.2equiv) in portions at 0 deg.C, stirring at room temperature for 2h, filtering with diatomaceous earth, adding saturated NaHCO into the filtrate3And Na2S2O3The solution was stirred for 10 minutes, and the organic layer was distilled under reduced pressure. After spin-drying, the resulting mixture was dissolved in 20ml of tetrahydrofuran, N2And lithium diisopropylamide (LDA, 3.8mL, dissolved in n-hexane at a concentration of 2.0M,1.5equiv) was added dropwise at-78 deg.C, monitored by TLC using saturated NH at-78 deg.C4Quenching with Cl solution, transferring the reaction solution to room temperature, extracting with ethyl acetate, and extracting with anhydrous Na2SO4After drying, the organic layer was distilled under reduced pressure and purified with a silica gel column to obtain white solid 15a (2.37g,3.8mmol) in 74% yield.1H NMR(CDCl3,400MHz):7.95–7.90(m,2H),7.62–7.57(m,1H),7.52–7.46(m,2H),6.06(dd,J＝4.9,1.2Hz,1H),4.11(dddd,J＝6.9,5.2,3.2,1.6Hz,1H),4.03(ddd,J＝4.8,3.1,1.6Hz,1H),3.87(ddd,J＝4.4,3.2,1.2Hz,1H),3.74(dd,J＝11.2,5.6Hz,1H),3.69(dd,J＝11.2,6.6Hz,1H),0.88(d,J＝0.9Hz,9H),0.84(d,J＝0.9Hz,9H),0.73(d,J＝0.9Hz,9H),0.12(s,3H),0.10(s,3H),0.02(s,3H),0.00(s,3H),-0.01(s,3H),and-0.03(s,3H).13C NMR(CDCl3,101MHz):151.50,138.64,133.68,129.06,128.58,106.59,83.15,68.78,66.86,60.54,25.99,25.91,25.70,18.37,18.13,17.89,-4.21,-4.43,-4.46,-4.83,-5.25,and-5.38.IR(thin film,cm-1):3005,2954,2929,2888,2857,1275,1259,1076,833,764,and 750cm-1.HRMS(DART-TOF)calculated for C30H56NaO6SSi3 +[M+Na]+m/z 651.2998, found 651.3001, melting point 103.4-105.6 ℃.
4. Synthesis of 1-phenylsulfonyl-3-triisopropylsiloxy-4, 6-O-di-tert-butylsilyl-D-glucal (15b)
Figure BDA0002023477080000072
Compound 15a (240mg,0.84mmol,1.0equiv) was dissolved in 20mL THF, followed by addition of tetrabutylammonium fluoride (TBAF, dissolved in THF, concentration 1.0M,3.3mL,3.3equiv), stirring the reaction solution at room temperature for 2h, distillation under reduced pressure, and purification on silica gel column (dichloromethane/methanol ═ 20:1) to give a white solid (260mg,0.91mmol, yield 91%).
The product obtained in the previous step (240mg,0.84mmol,1.0equiv) was dissolved in 5ml of dry DCM, pyridine (0.2ml,2.52mmol,3equiv) was added, the reaction was cooled to-35 ℃ and N was added2Dropwise adding under the protection condition (tBu)2Si(OTf)2(0.3ml,0.9mmol,1.08equiv), stirring at-35 deg.C for 6h, using saturated NH4The reaction was quenched with Cl solution. The reaction mixture was cooled to room temperature, extracted with ethyl acetate, and the organic layer was washed with anhydrous Na2SO4Drying, vacuum distillation, silica gel column purification (petroleum ether/ethyl acetate 3:1) gave the product as a colorless oil (354mg,0.83mmol, yield 99%).
The product obtained in the previous step (354mg,0.83mmol,1.0equiv) was dissolved in dry DMF (5ml), 35 ℃ and N2Imidazole (141mg,2.10mmol,2.5equiv) and triisopropylchlorosilane (TIPSCl, 0.32ml,1.49mmol,1.8equiv) were added dropwise under protection, stirred at 35 ℃ for 6h, saturated NH4The reaction solution is moved to room temperature, extracted by ethyl acetate, and the organic layer is anhydrous Na2SO4Drying and purification on silica gel column (3: 1 petroleum ether/ethyl acetate) gave 15b as a white solid (435mg,0.75mmol, 90% yield).1H NMR(CDCl3,400MHz):7.95–7.89(m,2H),7.70–7.63(m,1H),7.60–7.52(m,2H),5.97(d,J＝2.3Hz,1H),4.51(dd,J＝7.0,2.4Hz,1H),4.15(dd,J＝10.0,4.4Hz,1H),3.98(dd,J＝16.0,10.8Hz,1H),3.96(dd,J＝16.4,10.0Hz,1H),3.87(ddd,J＝14.8,10.0,3.6Hz,1H),1.16–1.08(m,21H),1.03(s,9H),0.95and(s,9H).13CNMR(CDCl3,101MHz):151.40,138.04,134..14,129.28,,128.83,111.27,76.40,75.45,70.95,65.41,27.51,26.97,22.82,19.96,18.23,18.21,and 12.54.IR(thin film,cm-1):2941,2863,1649,1471,1331,1275,1260,1160,1130,1111,1065,1006,1076,826,765,and750cm-1.HRMS(DART-TOF)calculated for C29H50NaO6SSi2 +[M+Na]+m/z 605.2759, found605.2765, melting point 146.7.0-148.8 ℃.
5. Synthesis of alpha-O-alkenylsulfones of the invention (Compounds 15c-15h)
The synthetic route of the alpha-O-alkenyl sulfone (15c-15h) of the invention is as follows:
Figure BDA0002023477080000081
wherein, the structural formulas of the corresponding sugar substrates SI-7 to SI-12 are respectively as follows:
Figure BDA0002023477080000082
Figure BDA0002023477080000083
the corresponding sugar substrate (1 eq) was placed in a round bottom flask and dried pyridine (sugar substrate concentration 0.3M) was added followed by acetic anhydride (10 eq). Stirring at room temperature for 15 hours until the reaction is completed. Quenching by adding water, extracting with ethyl acetate, washing with 1N hydrochloric acid for 3 times, washing with saturated sodium bicarbonate, drying with anhydrous sodium sulfate, filtering, and distilling under reduced pressure. And separating by column chromatography to obtain the product.
Dissolving the product (1 equivalent) obtained from the upper reaction in dichloromethane (the product concentration is 0.3M), cooling to 0 ℃ under the protection of nitrogen, and sequentially adding thiophenol (1.2 equivalents) and BF3·Et2O (1.5 equiv.). The reaction was carried out at room temperature for 8 hours, quenched with saturated ammonium chloride, extracted with dichloromethane, and washed with 0.3N sodium hydroxide and saturated brine in this order. Dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure. And (4) separating the product by column chromatography.
The product (1 eq) from the previous step was dissolved in DCM (product concentration 0.3M), cooled to 0 ℃ and M-chloroperoxybenzoic acid (2.2M) was added in portionsAmount), stirred at room temperature for 2 hours, filtered, and saturated NaHCO3The reaction was quenched in solution and Na was added2S2O3The solution was stirred for 10 minutes. The organic layer was then distilled under reduced pressure and the crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate 5: 1).
The product obtained in the previous step (1 eq) was dissolved in dry THF (product concentration 0.1M) at-78 ℃ and N2LDA (2.0M in n-hexane, 1.5 equivalents) was added dropwise under protection, monitored by TLC plate at-78 deg.C and saturated NH4The reaction was quenched with Cl. The reaction was allowed to warm to room temperature, extracted with ethyl acetate, and the organic layer was distilled under reduced pressure and purified by silica gel chromatography (petroleum ether/ethyl acetate ═ 7:1) to give the α -O-alkenylsulfone product 15c-15 h.
(1) 1-phenylsulfone-3, 4, 6-tribenzyloxy-D-galactan (15c)
Figure BDA0002023477080000091
1H NMR(CDCl3,400MHz):7.89(br d,J＝8Hz,2H),7.53(br t,J＝8Hz,1H),7.39–7.25(m,13H),7.22–7.17(m,2H),7.17–7.12(m,2H),6.20(dd,J＝2.8,1.2Hz,1H),4.84(d,J＝11.6Hz,1H),4.69(d,J＝12.0Hz,1H),4.63(d,J＝12.0Hz,1H),4.52(d,J＝11.6Hz,1H),4.33–4.27(m,3H),4.25(d,J＝12.0Hz,1H),3.97(dt,J＝3.7,1.6Hz,1H),3.63(dd,J＝10.2,6.4Hz,1H),and3.54(dd,J＝10.2,6.4Hz,1H).13C NMR(CDCl3,101MHz):151.44,138.25,138.18,137.82,137.68,133.68,128.99,128.62,128.46,128.33,128.32,128.01,127.84,127.74,127.67,127.65,127.58,107.14,78.69,73.59,73.43,71.58,71.52,70.46,and67.18.IR(thin film,cm-1):3028,3006,2989,2920,2865,1448,1324,1275,1260,1156,1100,1069,764,750,and 697cm-1.HRMS(DART-TOF)calculated forC32H32NaO6S+[M+Na]+m/z 579.1812, found 579.1820, melting point 73.0-74.3 deg.C.
(2) 1-phenylsulfonyl-3, 4-dibenzyloxy-D-fucosylene (15D)
Figure BDA0002023477080000092
1H NMR(CDCl3,400MHz):7.93–7.87(m,2H),7.57(t,J＝7.5Hz,1H),7.42(t,J＝7.7Hz,2H),7.37–7.25(m,8H),7.20–7.16(m,2H),6.19–6.16(m,1H),4.89(d,J＝12.0Hz,1H),4.74(d,J＝12.0Hz,1H),4.64(d,J＝12.0Hz,1H),4.57(d,J＝11.6Hz,1H),4.33(t,J＝3.2Hz,1H),4.26–4.19(m,1H),3.70–3.67(m,1H),and1.21(d,J＝6.8Hz,3H).13C NMR(CDCl3,101MHz):151.74,138.39,138.32,137.77,133.62,128.96,128.63,128.30,128.26,128.01,127.69,127.60,106.42,76.38,73.72,72.90,72.40,71.48,and15.72.IR(thin film,cm-1):3028,3005,2989,1320,1275,1260,1151,1108,1059,764,750,718,697,686,and 618cm-1.HRMS(DART-TOF)calculated for C26H26NaO5S+[M+Na]+m/z 473.1393,found 473.1401.
(3) 1-phenylsulfonyl-3, 4-dibenzyloxy-L-rhamnosene (15e)
Figure BDA0002023477080000093
1H NMR(CDCl3,400MHz):7.96–7.91(m,2H),7.66–7.61(m,1H),7.56–7.50(m,2H),7.37–7.23(m,10H),6.24–6.20(m,1H),4.78(d,J＝11.6Hz,1H),4.71(d,J＝11.6Hz,1H),4.62(d,J＝11.6Hz,1H),4.58(d,J＝11.6Hz,1H),4.26(dd,J＝6.0,2.8Hz,1H),4.12–4.04(m,1H),3.49–3.43(m,1H),and1.29(d,J＝6.4Hz,3H).13C NMR(CDCl3,101MHz):152.80,138.09,137.79,137.56,133.99,129.15,128.74,128.68,128.55,128.14,128.03,128.01,106.07,78.23,77.24,75.46,74.04,71.36,and16.89.IR(thin film,cm-1):3028,3005,2988,1446,1323,1275,1261,1159,1123,1060,764,750,724,697and 686cm-1.HRMS(DART-TOF)calculated for C26H26NaO5S+[M+Na]+m/z 473.1393, found 473.1401 melting point 62.8-64.4 deg.C
(4) 1-phenylsulfonyl-3, 4-dibenzyloxy-D-arabino-ene (15f)
Figure BDA0002023477080000101
1H NMR(CDCl3,400MHz):7.93–7.88(m,2H),7.65–7.59(m,1H),7.53–7.48(m,2H),7.35–7.23(m,10H),6.18(d,J＝4.8Hz,1H),4.70(s,2H),4.61(d,J＝12.0Hz,1H),4.54(d,J＝12.0Hz,1H),4.18(td,J＝4.2,3.6,1.0Hz,1H),4.11–4.05(m,2H),and3.72(ddd,J＝8.3,4.2,4.2Hz,1H).13C NMR(CDCl3,101MHz):153.88,137.95,137.90,137.61,134.02,129.20,128.65,128.62,128.58,128.06,127.99,127.74,105.49,71.77,71.66,71.57,67.43,and66.10.IR(thin film,cm-1):3028,3005,2989,2870,1324,1275,1260,1163,1124,1074,764,750,and 698cm-1.HRMS(DART-TOF)calculated for C25H24NaO5S+[M+Na]+m/z 459.1237, found 459.1238 melting point 105.8-107.3 deg.C
(5) 1-phenylsulfonyl-3, 4-dibenzyloxy-D-xylosene (15g)
Figure BDA0002023477080000102
1H NMR(CDCl3,400MHz):7.93(d,J＝7.8Hz,2H),7.62(t,J＝7.5Hz,1H),7.50(t,J＝7.7Hz,2H),7.38–7.25(m,8H),7.13(m,2H),6.24(d,J＝4.6Hz,1H),4.65(d,J＝12.0Hz,1H),4.56(d,J＝12.0Hz,1H),4.51(d,J＝12.0Hz,1H),4.48(d,J＝12.0Hz,1H),4.24(dd,J＝11.6,4.0Hz,1H),4.05–3.95(m,2H),and3.67(m,1H).13C NMR(CDCl3,101MHz):154.14,138.29,137.62,137.57,133.93,129.19,128.70,128.60,128.57,128.18,128.01,127.95,127.63,104.98,72.05,71.27,70.98,69.44,and66.52.IR(thin film,cm-1):3034,3006,2989,2870,1324,1275,1261,1161,1115,1076,764,749,and 698cm-1..HRMS(DART-TOF)calculated for C25H24NaO5S+[M+Na]+m/z 459.1237,found 459.1239.
(6) 1-phenylsulfonyl-hexabenzyloxy-D-malto-ene (15h)
Figure BDA0002023477080000103
1H NMR(CDCl3,400MHz):7.94–7.87(m,2H),7.43–7.35(m,3H),7.33–7.22(m,26H),7.17–7.09(m,4H),6.28–6.23(m,1H),5.22–5.16(m,1H),4.86(dd,J＝11.0,1.8Hz,1H),4.79–4.72(m,2H),4.67–4.59(m,2H),4.53(d,J＝4.5Hz,1H),4.50(d,J＝4.7Hz,1H),4.48–4.43(m,2H),4.41(d,J＝11.0Hz,1H),4.36–4.29(m,2H),4.29–4.24(m,1H),4.22–4.18(m,1H),4.12–4.08(m,1H),3.73(ddd,J＝9.2,5.1,2.0Hz,1H),3.67(ddd,J＝11.3,5.4,1.7Hz,1H),3.62(ddd,J＝11.3,5.4,1.7Hz,1H),3.60–3.57(m,2H),3.49–3.52(m,1H),3.49–3.46(m,1H),and3.37–3.32(m,1H).13C NMR(CDCl3,101MHz):152.68,138.84,138.44,138.19,138.03,137.96,137.93,137.36,133.95,129.14,128.65,128.59,128.55,128.46,128.42,128.38,128.34,128.06,128.00,127.95,127.91,127.87,127.76,127.75,127.65,127.57,104.83,97.02,81.80,79.82,79.54,77.45,75.67,75.08,73.50,73.38,73.22,72.84,71.00,70.66,70.51,68.13,and 67.07.IR(thin film,cm-1):3028,3006,2920,1453,1275,1260,1070,764,749,and 697cm-1.HRMS(DART-TOF)calculated forC60H60NaO11S+[M+Na]+m/z 1011.3749,found 1011.3751.1H NMR(400MHz,Chloroform-d)3.73(ddd,J＝9.2,5.1,2.0Hz,1H),3.67(ddd,J＝11.3,5.4,1.7Hz,1H).
6. Synthesis of open-chain alpha-O-alkenylsulfone (Compound 19)
Figure BDA0002023477080000111
Methoxymethylphenylsulfone (18,1.5equiv) was dissolved in THF (15mL), cooled to-78 deg.C under nitrogen, and LDA (9.0mmol,3.0equiv in n-hexane, 1.5M) was slowly added dropwise. After stirring for 15min, diethyl chlorophosphate (4.5mmol,1.5equiv) was added slowly. The reaction was stirred for 1 hour, and a solution of the corresponding aldehyde (3.0mmol,1.0equiv) in THF (5mL) was slowly added dropwise. Return to room temperature and stir overnight. Using saturated NH4Quenching Cl solution at low temperature, extracting with ethyl acetate, and extracting with anhydrous sodium sulfateDrying, filtering, distilling under reduced pressure, and separating by column chromatography to obtain compound 19 containing Z/E two configuration products, which can be separated by column chromatography.
(1) Preparation of Compound 19a
Referring to standard procedures, benzaldehyde (3.0mmol,318mg) and methoxymethylphenylsulfone (3.3mmol) were used as starting materials. Column chromatography was performed with petroleum ether/ethyl acetate 4:1 as eluent to give compound 19a, E/Z5: 1 as 771mg yellow oil in 94% yield.
(E) - (2-methoxy-2-phenylsulfonylvinyl) -benzene (E-19a)
Figure BDA0002023477080000112
1HNMR(CDCl3,400MHz)(E-isomer):8.01–7.95(m,2H),7.67–7.60(m,3H),7.58–7.52(m,2H),7.42–7.33(m,3H),7.23(s,1H),and3.87(s,3H).13C NMR(CDCl3,101MHz):153.33,139.11,133.73,131.55,130.00,129.96,129.26,129.00,128.50,122.68,and61.98.IR(thin film,cm-1):3005,2989,2942,2844,1446,1346,1304,1276,1260,1148,1094,1056,956,764,751,717,686,655,and 616cm-1.HRMS(DART-TOF)calculated forC15H14NaO3S+[M+Na]+m/z 297.0556,found 297.0561.
(Z) - (2-methoxy-2-phenylsulfonylvinyl) -benzene (Z-19a)
Figure BDA0002023477080000113
1H NMR(CDCl3,400MHz)(Z-isomer):7.83–7.77(m,2H),7.61–7.56(m,1H),7.49–7.44(m,2H),7.35–7.29(m,5H),6.32(s,1H),and3.74(s,3H).13C NMR(CDCl3,101MHz):154.48,139.43,133.62,132.03,129.79,128.83,128.61,127.85,127.82,111.60,and58.37.IR(thin film,cm-1):3059,3023,2935,1626,1446,1322,1307,1233,1138,1081,974,916,751,729,687,and 627cm-1.HRMS(DART-TOF)calculated for C15H14NaO3S+[M+Na]+m/z 297.0556,found 297.0556.
(2) Preparation of Compound 19b
Referring to standard procedure, 3-methylbutanal (3.0mmol,258mg) and methoxymethylphenylsulfone (3.3mmol) were used as starting materials. Column chromatography was performed with petroleum ether/ethyl acetate 4:1 as eluent to give compound 19b as a colorless oil 602mg in 79% yield, E/Z1.8: 1.
(E) - (1-methoxy-4-methyl-1-pentenyl) -sulfone-based benzene (E-19b)
Figure BDA0002023477080000121
1H NMR(CDCl3,400MHz)(E-isomer):7.94–7.88(m,2H),7.64–7.58(m,1H),7.56–7.50(m,2H),6.46(t,J＝7.8Hz,1H),3.80(s,3H),2.10(dd,J＝7.7,6.8Hz,2H),1.75(hept,J＝6.7Hz,1H),and0.92(d,J＝6.7Hz,6H).13C NMR(CDCl3,101MHz):154.08,139.27,133.50,129.09,128.21,126.18,63.11,34.46,28.12,and22.41.IR(thin film,cm-1):3070,2956,2870,1446,1322,1305,1160,1137,1092,1067,764,750,687,and 646cm-1.HRMS(DART-TOF)calculated for C13H18NaO3S+[M+Na]+m/z 277.0869,found 277.0873.
(Z) - (1-methoxy-4-methyl-1-pentenyl) -sulphonylbenzene (Z-19b)
Figure BDA0002023477080000122
1H NMR(CDCl3,400MHz)(Z-isomer):7.97–7.90(m,2H),7.66–7.59(m,1H),7.57–7.50(m,2H),5.31(t,J＝8.0Hz,1H),3.59(s,3H),2.59(dd,J＝8.0,6.9Hz,2H),1.71(hept,J＝6.7Hz,1H),and0.95(d,J＝6.7Hz,6H).13C NMR(CDCl3,101MHz):152.97,140.05,133.60,129.00,128.20,114.83,58.77,33.91,29.39,and22.29.IR(thin film,cm-1):2956,2869,1635,1464,1447,1319,1307,1142,1121,1084,975,758,732,and 687cm-1.HRMS(DART-TOF)calculated for C13H18NaO3S+[M+Na]+m/z 277.0869,found 277.0871.
(3) Preparation of Compound 19c
Using 4-triisopropylsilylbutyraldehyde (3.0mmol,733mg) and methoxymethylphenylsulfone (3.3mmol) as starting materials, according to standard procedures. Column chromatography was performed with petroleum ether/ethyl acetate 15:1 as eluent to give compound 19c, E/Z1.1: 1, 840mg of a colorless oil in 68% yield.
(E) - (1-methoxy-5-triisopropylsiloxy-1-pentenyl) -sulfone-benzene (E-19c)
Figure BDA0002023477080000123
1H NMR(CDCl3,400MHz)(E-isomer):7.95–7.87(m,2H),7.65–7.57(m,1H),7.56–7.48(m,2H),6.47(t,J＝7.7Hz,1H),3.82(s,3H),3.70(t,J＝6.1Hz,2H),2.34(q,J＝7.6Hz,2H),1.72–1.64(m,2H),1.12–1.06(m,3H),and1.04(d,J＝4.6Hz,18H).13C NMR(CDCl3,101MHz):153.93,139.24,133.52,129.11,128.33,126.92,63.23,62.43,31.87,22.37,18.08,and12.04.IR(thin film,cm-1):2941,2864,1318,1307,1275,1260,1156,1102,1063,881,764,750,723,and 685cm-1.HRMS(DART-TOF)calculated forC21H36NaO4SSi+[M+Na]+m/z 435.1996,found 435.2001.
(Z) - (1-methoxy-5-triisopropylsiloxy-1-pentenyl) -sulfonyl benzene (Z-19c)
Figure BDA0002023477080000124
1H NMR(CDCl3,400MHz)(Z-isomer):7.97–7.89(m,2H),7.66–7.59(m,1H),7.55–7.49(m,2H),5.35(t,J＝8.0Hz,1H),3.75(t,J＝6.4Hz,2H),3.58(s,3H),2.76(q,J＝7.8Hz,2H),1.75–1.67(m,2H),1.13–1.08(m,3H),and1.07(d,J＝4.6Hz,18H).13C NMR(CDCl3,101MHz):152.67,140.09,133.60,129.04,128.16,115.33,62.88,58.61,33.55,22.14,18.15,and12.11.IR(thin film,cm-1):2940,2864,1447,1325,1275,1260,1144,1099,882,764,750,and 687cm-1.HRMS(DART-TOF)calculated for C21H36NaO4SSi+[M+Na]+m/z 435.1996,found 435.2000.
(4) Preparation of Compound 19d
With reference to the standard procedure, 4-triisopropylsilylbutyraldehyde (3.0mmol,463mg) and methoxymethylphenylsulfone (3.3mmol) were used as starting materials. Column chromatography was performed with petroleum ether/ethyl acetate 15:1 as eluent to give compound 19d, E/Z1.9: 1, 811mg as a colorless oil in 84% yield.
(R, E) - (1-methoxy-4, 8-dimethyl-1, 7-nonadienyl) -sulphonylbenzene (E-19d)
Figure BDA0002023477080000131
1H NMR(CDCl3,400MHz)(E-isomer):7.96–7.86(m,2H),7.66–7.57(m,1H),7.56–7.48(m,2H),6.46(t,J＝7.7Hz,1H),5.04(tp,J＝6.9,1.2Hz,1H),3.81(s,3H),2.21(ddd,J＝14.5,7.5,5.8Hz,1H),2.13–2.04(m,1H),2.02–1.89(m,2H),1.67(s,3H),1.66–1.59(m,1H),1.58(s,3H),1.38–1.27(m,1H),1.25–1.13(m,1H),and0.90(d,J＝6.7Hz,3H).13C NMR(CDCl3,101MHz):154.14,139.35,133.51,131.65,129.13,128.26,126.29,124.31,63.14,36.80,32.72,32.47,25.80,25.54,19.70,and17.73.IR(thin film,cm-1):3006,2961,2914,1446,1318,1305,1275,1260,1154,1065,764,750,687,and 645cm-1.HRMS(DART-TOF)calculated for C18H26NaO3S+[M+Na]+m/z 345.1495,found 345.1499.
(R, Z) - (1-methoxy-4, 8-dimethyl-1, 7-nonadienyl) -sulphonylbenzene (Z-19d)
Figure BDA0002023477080000132
1H NMR(CDCl3,400MHz)(Z-isomer):7.97–7.90(m,2H),7.65–7.59(m,1H),7.56–7.50(m,2H),5.30(t,J＝8.0Hz,1H),5.12–5.05(m,1H),3.60(s,3H),2.68(ddd,J＝15.1,7.8,5.9Hz,1H),2.58(dt,J＝15.3,7.9Hz,1H),2.01(tp,J＝22.0,7.2Hz,2H),1.69(s,3H),1.60(s,3H),1.60–1.52(m,1H),1.39(dddd,J＝13.3,9.4,6.5,5.4Hz,1H),1.22(dddd,J＝13.6,9.3,7.9,6.0Hz,1H),and0.93(d,J＝6.7Hz,3H).13C NMR(CDCl3,101MHz):153.02,140.07,133.59,131.48,129.00,128.22,124.64,114.92,58.82,36.72,33.71,32.22,25.82,25.66,19.44,and17.78.IR(thin film,cm-1):2962,2912,2850,1635,1447,1322,1307,1275,1260,1143,1084,974,763,750,and 688cm-1.HRMS(DART-TOF)calculated forC18H26NaO3S+[M+Na]+m/z 345.1495,found 345.1498.
Example 2 Effect of different Process parameters on the Suzuki-Miyaura coupling reaction
1. Effect of ligands on Suzuki-Miyaura coupling reactions
The effect of different ligands on the Suzuki-Miyaura coupling reaction was investigated using the following reaction scheme as the basic reaction scheme.
Figure BDA0002023477080000141
The results are shown in Table 1, wherein the structural formulas of L1, L2, L3 and L4 are as follows:
Figure BDA0002023477080000142
TABLE 1 Effect of ligands on Suzuki-Miyaura coupling reactions
Figure BDA0002023477080000143
aReaction conditions(unless otherwise specified)：8a(0.05mmol，1.0equiv)，9(0.10mmol，2.0equiv)，THF(0.4mL).Yield and conversion weredetermined by1H NMR using 1，3，5-trimethoxybenzene as internal standard.bNi(cod)2instead of Ni(OTf)2.
From the results of table 1, it can be seen that: the ligand is Cy3P·HBF4(i.e., Cy in Table 1)3PHBF4) When the yield of the compound obtained is the highest, i.e. Cy3P·HBF4Is the optimal ligand for the application.
2. Effect of solvent on Suzuki-Miyaura coupling reactions
The effect of different solvents on the Suzuki-Miyaura coupling reaction was investigated using the following reaction scheme as the basic reaction scheme.
Figure BDA0002023477080000144
The reaction results are shown in table 2:
TABLE 2 Effect of solvents on Suzuki-Miyaura coupling reactions
Figure BDA0002023477080000151
aReaction conditions(unless otherwiise specified):8a(0.05mmol,1.0equiv),9(0.10mmol,2.0equiv),THF(0.4mL).Yield and conversion weredetermined by1H NMR using 1,3,5-trimethoxybenzene as internal standard.
As can be seen from Table 2: tert-butanol and tetrahydrofuran facilitate the reaction. Among them, tetrahydrofuran is preferable.
3. Effect of the catalyst on the Suzuki-Miyaura coupling reaction
The effect of different catalysts on the Suzuki-Miyaura coupling reaction was investigated using the following reaction scheme as the basic reaction scheme.
Figure BDA0002023477080000152
The reaction results are shown in table 3:
TABLE 3 Effect of different catalysts on the Suzuki-Miyaura coupling reaction
Figure BDA0002023477080000153
aReaction conditions(unless otherwise specified):8a(0.05mmol,1.0equiv),9(0.10mmol,2.0equiv),THF(0.4mL).Yield and conversion weredetermined by1H NMR using 1,3,5-trimethoxybenzene as internalstandard.bReactions were stirred at 80℃13h then 100℃10h.
As can be seen from Table 3: the Ni-containing catalyst facilitates the reaction as compared with other catalysts. Among them, the preferred catalyst is Ni (COD)2。
4. Effect of bases on Suzuki-Miyaura coupling reactions
The effect of different bases on the Suzuki-Miyaura coupling reaction was investigated using the following reaction scheme as the basic reaction scheme.
Figure BDA0002023477080000161
The reaction results are shown in table 4:
TABLE 4 Effect of different bases on the Suzuki-Miyaura coupling reaction
Figure BDA0002023477080000162
aReaction conditions(unless otherwise specified)：8a(0.05mmol，1.0equiv)，9(0.10mmol，2.0equiv)，THF(0.4mL).Yield and conversion were determinedby1H NMR using 1，3，5-trimethoxybenzene as internal standard.
As can be seen from Table 4: the most preferred base for this reaction is KOH.
5. Influence of temperature and time on Suzuki-Miyaura coupling reaction
The following reaction scheme was used as the basic reaction scheme to study the effect of different temperatures and times on the Suzuki-Miyaura coupling reaction.
Figure BDA0002023477080000163
The reaction results are shown in table 5:
TABLE 4 Effect of different temperatures and times on the Suzuki-Miyaura coupling reaction
Figure BDA0002023477080000171
aReaction conditions(unless otherwise specified)：8a(0.05mmol，10equiv)，9(0.10mmol，2.0 equiv)，THF(0.4mL)Yield and conversion were determinedby1H NMR using 1，3，5-trimethoxybenzene as internal standard.
As can be seen from Table 5: the optimal temperature of the reaction is 60-80 ℃, and the reaction time is 8-16 hours.
The optimization of the reaction conditions shows that the optimal conditions for realizing the Suzuki-Miyaura coupling reaction by using the electrophilic reagent alpha-O alkenyl sulfone are as follows: the metal catalyst is Ni (COD)2The ligand is Cy3P·HBF4The solvent is tetrahydrofuran or tert-butyl alcohol, the alkali is KOH, the reaction temperature is 60-80 ℃, and the reaction time is 8-16 h.
Example 3 preparation of aryl glycosides and open alkenyl ethers Using the alpha-O-alkenyl sulfones of the invention as electrophiles for Suzuki-Miyaura coupling reactions
The α -O-alkenylsulfone prepared in example 1 (1 equivalent), a commercially available arylboronic acid or boronic ester (2 equivalents), Cy3P·HBF4(0.2 eq.) was added to a screw-capped bottle containing a magnetic stirrer, and the cap was unscrewed and placed in a glove box. Adding Ni (COD)2(0.1 equiv.), KOH (2 equiv.), THF (0.2M, i.e., the concentration of α -O-alkenylsulfone in THF is 0.2M). After the small reaction bottle is screwed down, the glove box is moved out, and the bottle mouth is sealed by a black adhesive tape. The mixed system is stirred for 8 to 16 hours at the temperature of between 60 and 80 ℃. The reaction solution was then cooled to room temperature, diluted with ethyl acetate (10ml) and saturated NH4After washing with Cl, it was extracted with ethyl acetate (10mL × 3). Anhydrous Na for organic layer2SO4Drying, distilling under reduced pressure, and purifying by silica gel chromatographic column to obtain the target product. Wherein THF can be replaced by tert-butanol.
(1) 1-phenyl-3, 4, 6-tribenzyloxy-D-glucal alkene (10)
Figure BDA0002023477080000172
alpha-O-alkenylsulfone prepared in example 1 (0.20mmol,111mg), phenylboronic acid (0.40mmol, 48.8mg), Ni (COD) according to standard procedures2(0.02mmol，5.5mg)，Cy3PHBF4A mixture of (0.04mmol,14.7mg) and KOH (0.40mmol,22.4mg) in THF (1.0mL) was stirred at 60 deg.C for 12 h. Column chromatography was performed with petroleum ether/ethyl acetate (8: 1) as eluent, and isolation and purification gave compound 10(92.6mg, 0.19mmol, 94% yield) as a yellow oil.1HNMR(CDCl3，400MHz)：7.64-7.58(m，2H)，7.39-7.23(m，18H)，5.43(d，J＝3.2Hz，1H)，4.86(d，J＝11.2Hz，1H)，4.71(d，J＝11.6Hz，1H)，4.64(d，J＝11.6Hz，1H)，4.63(d，J＝12.4Hz，1H)，4.63(d，J＝11.6Hz，1H)，4.60(d，J＝12.4Hz，1H)，4.38(dd，J＝6.4，2.8Hz，1H)，4.26(ddd，J＝8.1，4.8，3.0Hz，1H)，3.98(dd，J＝8.4，6.0Hz，1H)，3.93(dd，J＝11.0，4.8Hz，1H)，and 3.88(dd，J＝10.9，3.0Hz，1H).13C NMR(CDCl3，101MHz)：152.87，138.65，138.42，134.68，128.81，128.55，128.52，128.48，128.25，128.06，127.86，127.84，127.79，127.76，127.69，125.41，96.18，77.48，76.76，74.55，73.66，73.61，70.62，and68.77.IR(thinfilm，cm-1)：3029，2930，2859，1652，1452，1276，1090，750，and 695cm-1.HRMS(DART-TOF)calculated for C33H32NaO4 +[M+Na]+m/z 515.2193，found 515.2187.
(2) 1-p-methoxyphenyl-3, 4, 6-tribenzyloxy-D-glucal alkene (13a)
Figure BDA0002023477080000181
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), p-methoxyphenylboronic acid (0.40mmol,60.8mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4(0.04mmol,14.7mg), and KOH (0.40 mm)ol,22.4mg) in THF (1.0mL) was stirred at 60 ℃ for 12 h. Column chromatography was performed with petroleum ether/ethyl acetate (eluent: 8:1) to give compound 13a as a colorless oil (85.7mg,0.16mmol, yield 82%).1HNMR(CDCl3,400MHz):7.56–7.52(m,2H),7.36–7.25(m,15H),6.87–6.82(m,2H),5.31(d,J＝3.2Hz,1H),4.85(d,J＝11.2Hz,1H),4.71(d,J＝11.2Hz,1H),4.68(d,J＝11.6Hz,1H),4.64(d,J＝12.0Hz,1H),4.62(d,J＝11.6Hz,1H),4.60(d,J＝12.0Hz,1H),4.37(dd,J＝6.0,3.2Hz,1H),4.25(ddd,J＝8.0,4.8,2.8Hz,1H),3.96(dd,J＝8.4,6.0Hz,1H),3.92(dd,J＝11.0,4.9Hz,1H),3.87(dd,J＝10.9,3.0Hz,1H),and3.79(s,3H).13C NMR(CDCl3,101MHz):160.17,152.72,138.72,138.43,128.52,128.50,128.46,128.05,127.84,127.81,127.77,127.71,127.67,127.34,126.80,113.60,94.50,77.37,76.79,74.59,73.57,70.48,68.80,and55.38.IR(thin film,cm-1):3439,3028,3006,1599,1275,1259,1089,1070,1026,833,764,749,and 696cm-1.HRMS(DART-TOF)calculated for C34H35O5 +[M+H]+m/z 523.2479,found 523.2485.
(3) 1-P-Dimethylaminophenyl-3, 4, 6-tribenzyloxy-D-glucal (13b)
Figure BDA0002023477080000182
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), p-dimethylaminobenzeneboronic acid pinacol ester (0.40mmol,98.9mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate (8: 1) as eluent, and separation and purification yielded compound 13b as a colorless oil (79.3mg,0.15mmol, 74% yield).1H NMR(CDCl3,400MHz):7.53–7.46(m,2H),7.37–7.24(m,15H),6.68–6.62(m,2H),5.26(d,J＝3.2Hz,1H),4.86(d,J＝11.2Hz,1H),4.71(d,J＝11.2Hz,1H),4.68(d,J＝10.4Hz,1H),4.66(d,J＝12.0Hz,1H),4.63(d,J＝10.4Hz,1H),4.61(d,J＝12.0Hz,1H),4.39(dd,J＝5.9,3.2Hz,1H),4.23(ddd,J＝8.1,4.7,3.1Hz,1H),3.95(dd,J＝10.8,4.8Hz,1H),3.95(dd,J＝11.2,3.2Hz,1H),and2.95(s,6H).13C NMR(CDCl3,101MHz):153.37,150.90,138.88,138.54,138.54,128.49,128.47,128.44,128.04,127.84,127.76,127.63,127.60,126.42,122.73,111.81,92.84,77.33,77.09,74.78,73.59,73.52,70.27,68.95,and40.50.IR(thin film,cm-1):3061,3028,2860,1609,1522,1359,1276,1260,1088,820,764,749,and 696cm-1.HRMS(DART-TOF)calculated for C35H38NO4 +[M+H]+m/z536.2795,found 536.2791.
(4) 1-p-fluorophenyl-3, 4, 6-tribenzyloxy-D-glucal (13c)
Figure BDA0002023477080000183
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), p-fluorophenylboronic acid (0.40mmol,56.0mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate (8: 1) as eluent, and separation and purification yielded compound 13c as a yellow oil (80.7mg,0.16mmol, yield 79%).1H NMR(CDCl3,400MHz):7.59–7.54(m,2H),7.36–7.25(m,15H),7.04–6.96(m,2H),5.35(d,J＝3.2Hz,1H),4.85(d,J＝11.6Hz,1H),4.70(d,J＝11.6Hz,1H),4.68(d,J＝12.0Hz,1H),4.62(d,J＝12.0Hz,1H),4.62(d,J＝12.0Hz,1H),4.59(d,J＝12.0Hz,1H),4.36(dd,J＝5.6,3.2Hz,1H),4.26(ddd,J＝8.0,4.8,2.8Hz,1H),3.96(dd,J＝8.4,6.0Hz,1H),3.91(dd,J＝10.9,5.0Hz,1H),and3.86(dd,J＝10.9,3.0Hz,1H).13C NMR(CDCl3,101MHz):163.19(d,J＝249.5Hz),151.99,138.58,138.32,130.86(d,J＝3.0Hz),128.56,128.53,128.49,128.06,127.88,127.85,127.79,127.74,127.32(d,J＝8.1Hz),115.26(d,J＝21.2Hz),95.94,77.43,76.53,74.43,73.62,73.58,70.70,and68.67.19F NMR(CDCl3,376MHz):–112.88.IR(thin film,cm-1):3461,3030,2864,1508,1275,1260,1228,1093,1027,839,764,749,and 697cm-1.HRMS(DART-TOF)calculated for C33H31FNaO4 +[M+Na]+m/z533.2099,found 533.2104.
(5) 1-p-trifluoromethylphenyl-3, 4, 6-tribenzyloxy-D-glucal ene (13D)
Figure BDA0002023477080000191
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), p-trifluoromethylphenylboronic acid (0.40mmol,76.0mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate (8: 1) as eluent to give compound 13d as a white solid (83.0mg,0.15mmol, 74% yield).1H NMR(CDCl3,400MHz):7.69(d,J＝8.4Hz,2H),7.57(d,J＝8.4Hz,2H),7.36–7.25(m,15H),5.50(d,J＝2.8Hz,1H),4.85(d,J＝11.6Hz,1H),4.71(d,J＝11.6Hz,1H),4.69(d,J＝11.6Hz,1H),4.64(d,J＝11.6Hz,1H),4.63(d,J＝12.0Hz,1H),4.59(d,J＝12.0Hz,1H),4.37(dd,J＝6.0,3.2Hz,1H),4.28(ddd,J＝8.0,4.8,2.8Hz,1H),3.98(dd,J＝8.4,6.0Hz,1H),3.92(dd,J＝10.9,4.9Hz,1H),and3.86(dd,J＝10.9,3.0Hz,1H).13C NMR(CDCl3,101MHz):151.45,138.45,138.26,138.04,130.57(q,J＝32.5Hz),128.60,128.56,128.52,128.07,127.93,127.87,127.80,127.79,125.62,125.22(q,J＝3.8Hz),124.24(q,J＝272.7Hz),98.20,77.55,76.40,74.33,73.71,73.61,70.96,and68.56.19F NMR(CDCl3,376MHz):–62.55.IR(thin film,cm-1):3031,2864,1322,1164,1109,1066,1027,1014,848,732,and 695cm-1.HRMS(DART-TOF)calculated for C34H31F3NaO4 +[M+Na]+m/z583.2067, found 583.2069, melting point 58.4-60.6 ℃.
(6)1- (3, 4-Dimethoxyphenyl) -3,4, 6-tribenzyloxy-D-glucal ene (13e)
Figure BDA0002023477080000192
alpha-O-alkenylsulfone 8a (0.20mmol,111mg),3, 4-dimethoxyphenylboronic acid (0.40mmol,72.8mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate (eluent: 8:1) to give compound 13e as a white solid (90.6mg,0.16mmol, yield 82%).1H NMR(CDCl3,400MHz):7.38–7.25(m,15H),7.19(dd,J＝8.4,2.0Hz,1H),7.11(d,J＝2.0Hz,1H),6.82(d,J＝8.4Hz,1H),5.31(d,J＝3.2Hz,1H),4.85(d,J＝11.6Hz,1H),4.72(d,J＝11.6Hz,1H),4.69(d,J＝11.2Hz,1H),4.65(d,J＝11.2Hz,1H),4.63(d,J＝12.4Hz,1H),4.62(d,J＝12.4Hz,1H),4.37(dd,J＝6.0,3.2Hz,1H),4.28(ddd,J＝8.4,4.8,3.2Hz,1H),3.96(dd,J＝7.6,4.8Hz,1H),3.92(dd,J＝10.8,5.2Hz,1H),3.88(dd,J＝10.8,3.2Hz,1H),3.87(s,3H),and3.85(s,3H).13C NMR(CDCl3,101MHz):152.64,149.70,148.67,138.72,138.41,138.36,128.53,128.52,128.45,128.06,127.85,127.83,127.73,127.70,127.68,118.33,110.78,108.76,94.92,77.36,76.66,74.58,73.55,73.53,70.65,68.78,56.02,and55.98.IR(thin film,cm-1):3464,3005,2863,1513,1453,1274,1261,1088,1070,1023,764,750,and 696cm-1.HRMS(DART-TOF)calculated for C35H37O6 +[M+H]+m/z553.2585, found 553.2587, melting point 100.7-102.1 deg.C.
(7) 1-m-methylphenyl-3, 4, 6-tribenzyloxy-D-glucal alkene (13f)
Figure BDA0002023477080000201
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), m-methylbenzylboronic acid (0.40mmol,54.4mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Performing column chromatography separation on the mixture,the eluent was petroleum ether/ethyl acetate 8:1, and was isolated and purified to give compound 13f as a white solid (76.0mg,0.15mmol, 75% yield).1H NMR(CDCl3,400MHz):7.43–7.39(m,2H),7.37–7.25(m,15H),7.23–7.18(m,1H),7.13–7.09(m,1H),5.41(d,J＝2.8Hz,1H),4.85(d,J＝11.6Hz,1H),4.71(d,J＝11.6Hz,1H),4.69(d,J＝11.6Hz,1H),4.64(d,J＝12.0Hz,1H),4.62(d,J＝11.6Hz,1H),4.60(d,J＝12.0Hz,1H),4.38(dd,J＝6.0,3.2Hz,1H),4.25(ddd,J＝8.0,4.4,3.2Hz,1H),3.97(dd,J＝8.8,6.4Hz,1H),3.92(dd,J＝11.0,4.9Hz,1H),3.88(dd,J＝11.1,3.3Hz,1H),and2.34(s,3H).13C NMR(CDCl3,101MHz):153.00,138.68,138.42,137.77,134.61,129.57,128.52,128.49,128.45,128.14,128.03,127.83,127.81,127.76,127.72,127.66,126.08,122.58,96.03,77.43,76.77,74.56,73.60,73.53,70.53,68.73,and21.57.IR(thin film,cm-1):3028,2862,1453,1275,1261,1089,1026,764,749,and 695cm-1.HRMS(DART-TOF)calculated for C34H34NaO4 +[M+Na]+m/z 529.2349, found 529.2350, melting point 43.5-46.6 ℃.
(8) 1-o-fluorophenyl-3, 4, 6-tribenzyloxy-D-glucal ene (13g)
Figure BDA0002023477080000202
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), O-fluorobenzeneboronic acid (0.40mmol,56.0mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate (eluent: 8:1) to give 13g (73.5mg,0.14mmol, yield 72%) of the compound as a white solid.1H NMR(CDCl3,400MHz):7.64(t,J＝7.6Hz,1H),7.39–7.23(m,16H),7.12(t,J＝7.6Hz,1H),7.05(dd,J＝11.6,8.4Hz,1H),5.62(d,J＝3.2Hz,1H),4.87(d,J＝11.6Hz,1H),4.71(d,J＝11.6Hz,1H),4.70(d,J＝11.6Hz,1H),4.64(d,J＝12.0Hz,1H),4.62(d,J＝11.6Hz,1H),4.59(d,J＝12.0Hz,1H),4.41(dd,J＝6.4,2.4Hz,1H),4.24(ddd,J＝8.6,4.8,2.0Hz,1H),3.99(dd,J＝8.6,6.2Hz,1H),3.99(dd,J＝10.8,4.8Hz,1H),and 3.89(dd,J＝10.8,2.0Hz,1H).13C NMR(CDCl3,101MHz):160.12(d,J＝252.5Hz),147.87(d,J＝4.0Hz),138.52,138.40,138.36,129.94(d,J＝9.1Hz),128.87(d,J＝3.0Hz),128.51,128.49,128.45,128.03,127.89,127.81,127.77,127.72,127.67,123.94(d,J＝3.0Hz),122.77(d,J＝11.1Hz),116.07(d,J＝23.2Hz),101.70(d,J＝11.1Hz),77.55,76.80,74.30,73.68,73.55,70.45,and68.70.19F NMR(CDCl3,376MHz):–112.84.IR(thin film,cm-1):3087,2918,2863,1492,1452,1091,1049,1026,732,and 695cm-1.HRMS(DART-TOF)calculatedfor C33H31FNaO4 +[M+Na]+m/z 533.2099, found 533.2101, melting point 59.1-62.3 deg.C.
(9)1- (1-naphthyl) -3,4, 6-tribenzyloxy-D-glucal (13h)
Figure BDA0002023477080000211
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), 1-naphthaleneboronic acid (0.40mmol,68.8mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate (eluent: 8:1) to give the compound as colorless oil 13h (97.6mg,0.18mmol, yield 90%).1H NMR(CDCl3,400MHz):8.25(dd,J＝8.4,1.4Hz,1H),7.84–7.78(m,2H),7.54(dd,J＝7.2,1.4Hz,1H),7.46–7.38(m,3H),7.37–7.24(m,15H),5.22(d,J＝3.2Hz,1H),4.92(d,J＝11.2Hz,1H),4.77(d,J＝11.2Hz,1H),4.71(d,J＝12.0Hz,1H),4.63(d,J＝11.6Hz,1H),4.60(d,J＝12.0Hz,1H),4.56(d,J＝12.0Hz,1H),4.44(dd,J＝6.4,3.2Hz,1H),4.41(ddd,J＝8.0,4.8,2.4Hz,1H),4.13(dd,J＝8.4,6.4Hz,1H),3.99(dd,J＝10.8,4.8Hz,1H),and3.89(dd,J＝10.8,2.8Hz,1H).13C NMR(CDCl3,101MHz):154.51,138.54,138.50,138.40,133.78,133.74,131.37,129.42,128.55,128.53,128.43,128.26,128.03,127.89,127.84,127.77,127.69,127.62,126.92,126.34,126.13,125.93,125.12,100.77,77.75,76.76,74.60,73.78,73.55,70.72,and68.81.IR(thin film,cm-1):3028,3006,2861,1453,1275,1260,1071,1026,764,749,and 695cm-1.HRMS(DART-TOF)calculated forC37H34NaO4 +[M+Na]+m/z565.2349,found 565.2358.
(10) 1-o-methylphenyl-3, 4, 6-tribenzyloxy-D-glucal (13i)
Figure BDA0002023477080000212
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), O-tolylboronic acid (0.40mmol,54.4mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate (eluent: 8:1) to give compound 13i (81.1mg,0.16mmol, yield 80%) as a colorless oil.1H NMR(CDCl3,400MHz):7.37–7.23(m,16H),7.22–7.18(m,1H),7.16–7.11(m,2H),5.01(d,J＝2.9Hz,1H),4.87(d,J＝11.6Hz,1H),4.71(d,J＝11.6Hz,1H),4.68(d,J＝11.6Hz,1H),4.61(d,J＝11.6Hz,1H),4.58(d,J＝12.0Hz,1H),4.53(d,J＝12.0Hz,1H),4.38(dd,J＝6.2,2.9Hz,1H),4.23(ddd,J＝8.8,4.8,2.6Hz,1H),4.01(dd,J＝8.8,6.2Hz,1H),3.91(dd,J＝10.8,4.8Hz,1H),3.84(dd,J＝10.8,2.7Hz,1H),and2.37(s,3H).13C NMR(CDCl3,101MHz):155.36,138.60,138.51,138.35,136.81,135.58,130.44,129.16,128.79,128.52,128.48,128.41,127.97,127.87,127.77,127.73,127.72,127.62,125.55,99.60,77.49,76.99,74.62,73.73,73.54,70.56,68.90,and20.37.IR(thin film,cm-1):3006,2989,2862,1275,1260,1086,1041,1027,764,747,and 695cm-1.HRMS(DART-TOF)calculated for C34H34NaO4 +[M+Na]+m/z 529.2349,found 529.2355.
(11)1- (3, 4-methylenedioxyphenyl) -3,4, 6-tribenzyloxy-D-glucal ene (13j)
Figure BDA0002023477080000213
alpha-O-alkenylsulfone 8a (0.20mmol,111mg),3, 4-methylenedioxyphenylboronic acid (0.40mmol,66.4mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate (eluent: 8:1) to give compound 13j (87.9mg,0.16mmol, yield 82%) as a white solid.1H NMR(CDCl3,400MHz):7.36–7.27(m,15H),7.13(dd,J＝8.4,1.6Hz,1H),7.07(d,J＝1.6Hz,1H),6.75(d,J＝8.4Hz,1H),5.93(s,2H),5.28(d,J＝3.2Hz,1H),4.85(d,J＝11.6Hz,1H),4.70(d,J＝11.6Hz,1H),4.67(d,J＝11.6Hz,1H),4.63(d,J＝12.0Hz,1H),4.61(d,J＝11.6Hz,1H),4.59(d,J＝12.0Hz,1H),4.35(dd,J＝6.0,3.2Hz,1H),4.23(ddd,J＝8.0,4.8,3.2Hz,1H),3.95(dd,J＝8.4,6.0Hz,1H),3.90(dd,J＝10.9,4.9Hz,1H),and3.85(dd,J＝10.9,3.0Hz,1H).13C NMR(CDCl3,101MHz):152.55,148.14,147.69,138.65,138.39,138.37,129.02,128.54,128.51,128.48,128.05,127.85,127.84,127.79,127.74,127.70,119.54,108.02,106.07,101.27,95.09,77.43,76.76,74.54,73.60,73.58,70.56,and68.71.IR(thin film,cm-1):3063,2867,1488,1444,1095,1037,1028,932,732,and 695cm-1.HRMS(DART-TOF)calculated for C34H32NaO6 +[M+Na]+m/z 559.2091, found 559.2095, melting point 52.2-55.4 ℃.
(12) 1-vinyl-3, 4, 6-tribenzyloxy-D-glucal ene (13k)
Figure BDA0002023477080000221
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), vinylboronic acid pinacol ester (0.40mmol,61.6mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4(0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL)The mixture was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded compound 13k (42.4mg,0.01mmol, 48% yield) as a colorless oil.1H NMR(CDCl3,400MHz):7.35–7.25(m,15H),6.07(dd,J＝17.2,10.8Hz,1H),5.63(dd,J＝17.2,1.6Hz,1H),5.16(dd,J＝10.8,1.7Hz,1H),4.92(d,J＝3.1Hz,1H),4.83(d,J＝11.4Hz,1H),4.68(d,J＝11.4Hz,1H),4.63(d,J＝11.6Hz,1H),4.61(d,J＝12.0Hz,1H),4.58(d,J＝12.0Hz,1H),4.56(d,J＝11.6Hz,1H),4.28(dd,J＝6.1,3.1Hz,1H),4.13(ddd,J＝8.1,4.7,3.0Hz,1H),3.90(dd,J＝8.6,6.1Hz,1H),3.86(dd,J＝11.0,4.8Hz,1H),3.82(dd,J＝11.0,3.1Hz,1H).13C NMR(CDCl3,101MHz):151.71,138.54,138.47,138.40,131.36,128.53,128.51,128.47,128.07,127.85,127.76,127.67,115.64,100.98,77.21,76.65,74.54,73.74,73.60,70.63,68.72.IR(thin film,cm-1):3032,2917,2861,1689,1264,1228,1111,1097,908,729,and 697cm-1.HRMS(DART-TOF)calculated for C49H51N2O6 +[M+H]+m/z 763.3742,found 763.3745.
(13) 1-allyl-3, 4, 6-tribenzyloxy-D-glucal (13l)
Figure BDA0002023477080000222
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), allylboronic acid pinacol ester (0.40mmol,67.2mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded 13l (77.6mg,0.17mmol, 85% yield) of the compound as a colorless oil.1H NMR(CDCl3,400MHz):7.44–7.23(m,15H),5.84(ddt,J＝16.9,10.1,6.8Hz,1H),5.18–5.00(m,2H),4.80(d,J＝11.5Hz,1H),4.70(d,J＝2.9Hz,1H),4.68–4.48(m,5H),4.20–4.13(m,1H),4.10(ddd,J＝8.1,5.0,3.1Hz,1H),3.84(dd,J＝8.1,5.8Hz,1H),3.81(dd,J＝10.9,5.0Hz,1H),3.75(dd,J＝10.8,3.0Hz,1H),2.84(d,J＝6.8Hz,2H).13C NMR(CDCl3,101MHz):154.71,138.64,138.42,138.39,133.84,128.48,128.44,128.02,127.82,127.80,127.78,127.67,117.25,95.71,77.07,76.10,74.36,73.54,73.49,70.44,68.71,and 38.06.IR(thin film,cm-1):3029,2864,1673,1453,1261,1095,1027,916,743,and 696cm-1.HRMS(DART-TOF)calculated for C30H32NaO4 +[M+Na]+m/z 479.2193,found479.2196.
(14) 1-p-cyanophenyl-3, 4, 6-tribenzyloxy-D-glucal ene (13m)
Figure BDA0002023477080000231
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), p-cyanobenzeneboronic acid (0.40mmol,58.8mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give 13m (72.5mg,0.14mmol, 70% yield) as a white solid.1H NMR(CDCl3,400MHz):7.67(d,J＝8.0Hz,2H),7.59(d,J＝8.8Hz,2H),7.35–7.27(m,15H),5.53(d,J＝3.2Hz,1H),4.84(d,J＝11.2Hz,1H),4.70(d,J＝11.2Hz,1H),4.69(d,J＝11.6Hz,1H),4.64(d,J＝11.6Hz,1H),4.61(d,J＝12.0Hz,1H),4.58(d,J＝12.0Hz,1H),4.35(dd,J＝6.0,3.2Hz,1H),4.28(ddd,J＝8.0,4.8,2.8Hz,1H),3.97(dd,J＝8.4,6.0Hz,1H),3.91(dd,J＝10.9,5.0Hz,1H),and3.85(dd,J＝10.9,3.0Hz,1H).13C NMR(CDCl3,101MHz):150.86,138.83,138.31,138.14,138.12,132.07,128.59,128.55,128.50,128.47,128.04,127.94,127.90,127.84,127.80,127.77,125.79,118.87,112.08,99.27,77.53,76.19,74.17,73.70,73.57,71.05,and68.43.IR(thin film,cm-1):3006,2989,2864,1275,1260,1097,764,749,and 698cm-1.HRMS(DART-TOF)calculated forC34H31NNaO4 +[M+Na]+m/z 540.2145, found 540.2146, melting point 103.5-106.6 ℃.
(15) 1-p-methoxycarbonylphenyl-3, 4, 6-tribenzyloxy-D-glucal ene (13n)
Figure BDA0002023477080000232
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), p-methoxycarbonylphenylboronic acid (0.40mmol,72.0mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give compound 13n (89.1mg,0.16mmol, 81% yield) as a white solid.1H NMR(CDCl3,400MHz):8.00(d,J＝8.4Hz,2H),7.66(d,J＝8.4Hz,2H),7.40–7.24(m,15H),5.53(d,J＝3.2Hz,1H),4.85(d,J＝11.2Hz,1H),4.71(d,J＝11.2Hz,1H),4.70(d,J＝11.6Hz,1H),4.64(d,J＝11.6Hz,1H),4.62(d,J＝12.4Hz,1H),4.59(d,J＝12.4Hz,1H),4.37(dd,J＝6.4,2.8Hz,1H),4.27(ddd,J＝8.4,4.8,3.2Hz,1H),3.98(dd,J＝8.4,6.0Hz,1H),3.87(dd,J＝10.6,4.8Hz,1H),3.90(s,3H),and 3.87(dd,J＝10.6,2.8Hz,1H).13C NMR(CDCl3,101MHz):166.89,151.76,138.85,138.46,138.26,130.15,129.57,128.57,128.53,128.49,128.05,127.89,127.85,127.83,127.78,127.75,125.21,98.32,77.51,76.49,74.32,73.70,73.57,70.87,68.54,and52.22.IR(thin film,cm-1):3029,2862,1718,1274,1099,1026,1016,732,and 695cm-1.HRMS(DART-TOF)calculated forC35H34NaO6 +[M+Na]+m/z 573.2248, found 573.2249, melting point 65.9-68.1 deg.C.
(16)1- (4- (2-hydroxypropan-2-yl) phenyl) -3,4, 6-tribenzyloxy-D-glucal (13o)
Figure BDA0002023477080000241
alpha-O-alkenylsulfone 8a (0.20mmol,111mg),4- (2-hydroxypropan-2-yl) phenylboronic acid (0.40mmol,72.0mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded compound 13o as a colorless oil (78.2mg,0.14mmol, yield 71%).1H NMR(CDCl3,400MHz):7.57(d,J＝8.4Hz,2H),7.44(d,J＝8.4Hz,2H),7.37–7.27(m,15H),5.41(d,J＝3.2Hz,1H),4.86(d,J＝11.2Hz,1H),4.71(d,J＝11.2Hz,1H),4.70(d,J＝12.0Hz,1H),4.63(d,J＝12.0Hz,1H),4.62(d,J＝12.0Hz,1H),4.60(d,J＝12.0Hz,1H),4.38(dd,J＝6.0,2.8Hz,1H),4.26(ddd,J＝8.4,4.8,3.2Hz,1H),3.97(dd,J＝8.4,6.0Hz,1H),3.92(dd,J＝10.9,4.8Hz,1H),3.88(dd,J＝11.0,3.1Hz,1H),1.82–1.74(br s,1H),and1.57(s,6H).13C NMR(CDCl3,101MHz):152.70,149.80,138.67,138.43,133.16,128.57,128.53,128.50,128.07,127.89,127.86,127.80,127.78,127.71,125.34,124.35,96.00,77.48,76.77,74.58,73.66,73.62,72.62,70.63,68.79,and31.83.IR(thin film,cm-1):3414,3030,2972,2865,1275,1261,1088,1071,1026,1015,748,733,and 696cm-1.HRMS(DART-TOF)calculated for C36H38NaO5 +[M+Na]+m/z 573.2611,found 573.2615.
(17) 1-p-acetylphenyl-3, 4, 6-tribenzyloxy-D-glucal ene (13p)
Figure BDA0002023477080000242
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), p-acetylphenylboronic acid (0.40mmol,65.6mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give compound 13p (78.1mg,0.15mmol, 73% yield) as a white solid.1H NMR(CDCl3,400MHz):7.94–7.89(m,2H),7.71–7.66(m,2H),7.37–7.28(m,15H),5.55(d,J＝3.2Hz,1H),4.85(d,J＝11.2Hz,1H),4.72(d,J＝11.2Hz,1H),4.70(d,J＝11.6Hz,1H),4.66(d,J＝11.6Hz,1H),4.63(d,J＝12.4Hz,1H),4.60(d,J＝12.4Hz,1H),4.38(dd,J＝6.0,3.2Hz,1H),4.28(ddd,J＝8.4,4.8,3.2Hz,1H),3.98(dd,J＝8.4,6.0Hz,1H),3.92(dd,J＝10.9,4.9Hz,1H),3.88(dd,J＝10.9,3.0Hz,1H),and2.59(s,3H).13C NMR(CDCl3,101MHz):197.73,151.68,138.97,138.44,138.26,138.24,137.02,128.58,128.54,128.50,128.36,128.06,127.91,127.86,127.78,127.76,125.40,98.55,77.53,76.48,74.32,73.71,73.60,70.93,68.57,and26.76.IR(thin film,cm-1):3006,2989,2861,1680,1604,1275,1260,1089,1026,764,749,and 696cm-1.HRMS(DART-TOF)calculated for C35H34NaO5 +[M+Na]+m/z 557.2298, found 557.2300, melting point 88.2-90.3 ℃.
(18) 1-P-Dimethylcarbamoylphenyl-3, 4, 6-tribenzyloxy-D-glucal ene (13q)
Figure BDA0002023477080000243
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), p-dimethylcarbamoylphenylboronic acid (0.40mmol,77.2mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded compound 13q (50.7mg,0.09mmol, 45% yield) as a colorless oil.1H NMR(CDCl3,400MHz):7.63(d,J＝8.4Hz,2H),7.40–7.37(m,2H),7.36–7.26(m,15H),5.47(d,J＝3.2Hz,1H),4.86(d,J＝11.2Hz,1H),4.72(d,J＝11.2Hz,1H),4.69(d,J＝12.0Hz,1H),4.65(d,J＝12.0Hz,1H),4.62(d,J＝12.0Hz,1H),4.60(d,J＝12.0Hz,1H),4.38(dd,J＝6.0,3.6Hz,1H),4.27(ddd,J＝8.4,4.8,3.2Hz,1H),3.98(dd,J＝8.4,6.0Hz,1H),3.92(dd,J＝10.9,4.9Hz,1H),3.87(dd,J＝10.9,3.0Hz,1H),3.10(s,3H),and2.95(s,3H).13C NMR(CDCl3,101MHz):171.38,152.01,138.50,138.29,138.29,136.45,135.77,128.55,128.51,128.47,128.04,127.86,127.84,127.80,127.77,127.72,127.13,125.29,97.19,77.48,76.57,74.41,73.67,73.58,70.78,68.64,39.64,and35.49.IR(thin film,cm-1):3006,2989,2862,1629,1275,1261,1079,764,749,and696cm-1.HRMS(DART-TOF)calculated for C36H37NNaO5 +[M+Na]+m/z 586.2564,found586.2572.
(19)1- (Dibenzothien-4-yl) -3,4, 6-tribenzyloxy-D-glucal ene (13r)
Figure BDA0002023477080000251
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), dibenzothiophene-4-boronic acid (0.40mmol,91.2mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give compound 13r (99.3mg,0.17mmol, 83% yield) as a white solid.1H NMR(CDCl3,400MHz):8.14–8.08(m,2H),7.82–7.76(m,1H),7.66(dd,J＝7.6,1.2Hz,1H),7.45–7.24(m,18H),5.61(d,J＝2.8Hz,1H),4.91(d,J＝11.6Hz,1H),4.76(d,J＝11.6Hz,1H),4.75(d,J＝11.6Hz,1H),4.70(d,J＝11.6Hz,1H),4.67(d,J＝12.0Hz,1H),4.64(d,J＝12.0Hz,1H),4.48(dd,J＝6.4,3.2Hz,1H),4.37(ddd,J＝8.8,6.4,3.2Hz,1H),4.11(dd,J＝8.6,6.4Hz,1H),4.04(dd,J＝11.2,4.0Hz,1H),and 4.01(dd,J＝11.2,4.0Hz,1H).13C NMR(CDCl3,101MHz):152.91,140.32,138.63,138.45,138.40,137.12,136.61,135.11,130.12,128.57,128.52,128.45,128.07,127.93,127.85,127.78,127.65,126.90,125.23,124.43,124.33,122.44,122.03,121.56,99.23,77.97,77.10,74.56,73.86,73.69,70.64,and68.76.IR(thin film,cm-1):3028,3006,2859,1275,1260,1089,1041,1026,764,749,and 695cm-1.HRMS(DART-TOF)calculated for C39H34NaO4S+[M+Na]+m/z621.2070, found 621.2079 melting point 75.6-78.1 deg.C.
(20)1- (thien-3-yl) -3,4, 6-tribenzyloxy-D-glucal ene (13s)
Figure BDA0002023477080000252
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), thiophene-3-boronic acid (0.40mmol,51.2mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded compound 13s (89.8mg,0.18mmol, yield 90%) as a yellow oil.1H NMR(CDCl3,400MHz):7.47(dd,J＝3.2,1.2Hz,1H),7.36–7.25(m,15H),7.24–7.21(m,1H),7.20–7.17(m,1H),5.30(d,J＝3.2Hz,1H),4.84(d,J＝11.6Hz,1H),4.70(d,J＝11.6Hz,1H),4.67(d,J＝12.0Hz,1H),4.63(d,J＝12.0Hz,1H),4.60(d,J＝12.0Hz,1H),4.59(d,J＝12.0Hz,1H),4.35(dd,J＝6.0,3.2Hz,1H),4.25(ddd,J＝8.2,4.8,3.2Hz,1H),3.95(dd,J＝8.4,6.0Hz,1H),3.90(dd,J＝10.9,4.9Hz,1H),and 3.85(dd,J＝11.0,3.0Hz,1H).13C NMR(CDCl3,101MHz):149.52,138.62,138.37,138.35,136.88,128.53,128.51,128.47,128.05,127.84,127.76,127.74,127.69,125.70,124.99,122.36,95.87,77.30,76.41,74.39,73.60,73.56,70.60,and68.70.IR(thin film,cm-1):3434,3028,3006,2864,1275,1260,1087,1071,1026,764,749,and 695cm-1.HRMS(DART-TOF)calculated forC31H30NaO4S+[M+H]+m/z 521.1757,found 521.1765.
(21)1- (benzofuran-5-yl) -3,4, 6-tribenzyloxy-D-glucal ene (13t)
Figure BDA0002023477080000261
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), benzofuran-5-boronic acid (0.40mmol,64.8mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 deg.C for 1For 2 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give 13t (91.5mg,0.17mmol, 86% yield) as a white solid.1H NMR(CDCl3,400MHz):7.86(d,J＝1.6Hz,1H),7.59(d,J＝2.0Hz,1H),7.55(dd,J＝8.4,1.6Hz,1H),7.45–7.41(m,1H),7.37–7.26(m,15H),6.74(dd,J＝2.0,0.8Hz,1H),5.42(d,J＝3.2Hz,1H),4.87(d,J＝11.2Hz,1H),4.72(d,J＝11.2Hz,1H),4.71(d,J＝12.0Hz,1H),4.65(d,J＝12.0Hz,1H),4.63(d,J＝12.0Hz,1H),4.61(d,J＝12.0Hz,1H),4.40(dd,J＝6.0,3.2Hz,1H),4.30(ddd,J＝8.4,4.8,2.8Hz,1H),3.99(dd,J＝8.4,5.6Hz,1H),3.95(dd,J＝10.9,4.9Hz,1H),and 3.90(dd,J＝10.9,3.0Hz,1H).13C NMR(CDCl3,101MHz):155.34,153.23,145.62,138.69,138.41,129.85,128.54,128.51,128.47,128.06,127.85,127.83,127.80,127.74,127.69,127.41,122.24,118.59,111.05,106.99,95.59,77.48,76.80,74.60,73.60,73.58,70.54,and68.79.IR(thin film,cm-1):3030,2865,1264,1110,1091,1027,730,and 696cm-1.HRMS(DART-TOF)calculated forC35H32NaO5 +[M+Na]+m/z 555.2142, found 555.2151, melting point 65.4-67.8 ℃.
(22)1- (benzofuran-3-yl) -3,4, 6-tribenzyloxy-D-glucal ene (13u)
Figure BDA0002023477080000262
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), benzofuran-3-boronic acid (0.40mmol,64.8mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give 13u (80.0mg,0.15mmol, yield 75%) as a white solid.1H NMR(CDCl3,400MHz):7.83(s,1H),7.70–7.66(m,1H),7.49–7.45(m,1H),7.39–7.28(m,15H),7.28–7.21(m,2H),5.41(d,J＝2.8Hz,1H),4.88(d,J＝11.2Hz,1H),4.73(d,J＝11.2Hz,1H),4.71(d,J＝12.0Hz,1H),4.67(d,J＝12.0Hz,1H),4.63(d,J＝12.0Hz,1H),4.60(d,J＝12.0Hz,1H),4.41(dd,J＝6.0,3.0Hz,1H),4.29(ddd,J＝8.2,4.8,2.8Hz,1H),4.00(dd,J＝8.4,6.0Hz,1H),3.93(dd,J＝10.9,5.1Hz,1H),and 3.87(dd,J＝10.9,2.9Hz,1H).13C NMR(CDCl3,101MHz):155.74,147.50,143.84,138.72,138.36,138.32,128.61,128.55,128.51,128.08,127.91,127.89,127.82,127.75,124.81,124.64,123.19,121.22,117.02,111.79,97.64,77.29,76.72,74.50,73.71,73.60,70.83,and68.76.IR(thinfilm,cm-1):3028,3006,2861,1665,1451,1275,1260,1095,1040,1026,764,749,and695cm-1.HRMS(DART-TOF)calculated for C35H32NaO5 +[M+Na]+m/z 555.2142, found555.2147, mp 63.2-65.9 deg.C.
(23)1- (dibenzofuran-4-yl) -3,4, 6-tribenzyloxy-D-glucal ene (13v)
Figure BDA0002023477080000271
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), dibenzofuran-4-boronic acid (0.40mmol,84.8mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give 13v (100.2mg,0.17mmol, 86% yield) as a white solid.1H NMR(CDCl3,400MHz):7.96–7.91(m,1H),7.90–7.87(m,1H),7.84–7.79(m,1H),7.60–7.55(m,1H),7.48–7.41(m,3H),7.39–7.25(m,15H),6.34(d,J＝2.8Hz,1H),4.92(d,J＝11.6Hz,1H),4.80(d,J＝11.6Hz,1H),4.77(d,J＝11.6Hz,1H),4.74(d,J＝11.6Hz,1H),4.69(d,J＝12.0Hz,1H),4.64(d,J＝12.0Hz,1H),4.56(dd,J＝6.0,3.2Hz,1H),4.33(ddd,J＝8.4,4.4,3.2Hz,1H),4.08(dd,J＝8.4,6.0Hz,1H),3.99(dd,J＝11.0,4.7Hz,1H),and3.94(dd,J＝11.1,2.9Hz,1H).13C NMR(CDCl3,101MHz):156.07,152.83,148.38,138.75,138.48,138.45,128.56,128.53,128.49,128.11,128.00,127.84,127.82,127.76,127.70,127.26,125.05,124.01,123.04,122.71,120.77,120.68,119.74,111.92,101.82,77.60,77.18,74.42,73.74,73.64,70.50,and68.86.IR(thin film,cm-1):3062,3029,2861,1450,1189,1086,1045,1026,746,732,and 695cm-1.HRMS(DART-TOF)calculated for C39H34NaO5 +[M+Na]+m/z 605.2298, found 605.2303, melting point 113.4-115.5 ℃.
(24) 1-m-pyridine-3, 4, 6-tribenzyloxy-D-glucal alkene (13w)
Figure BDA0002023477080000272
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), 3-pyridineboronic acid (0.40mmol,49.2mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give compound 13w (58.2mg,0.12mmol, 59% yield) as a yellow oil.1H NMR(CDCl3,400MHz):8.84(d,J＝2.2Hz,1H),8.53(dd,J＝4.9,1.6Hz,1H),7.85(dt,J＝8.0,2.0Hz,1H),7.36–7.25(m,15H),7.25–7.22(m,1H),5.47(d,J＝3.2Hz,1H),4.85(d,J＝11.6Hz,1H),4.71(d,J＝11.6Hz,1H),4.68(d,J＝12.0Hz,1H),4.65(d,J＝12.0Hz,1H),4.62(d,J＝12.0Hz,1H),4.59(d,J＝12.0Hz,1H),4.36(dd,J＝5.9,3.2Hz,1H),4.28(ddd,J＝8.1,4.9,2.9Hz,1H),3.98(dd,J＝8.3,5.9Hz,1H),3.92(dd,J＝10.9,4.9Hz,1H),and 3.86(dd,J＝11.0,2.9Hz,1H).13C NMR(CDCl3,101MHz):150.42,149.68,146.93,138.39,138.21,138.19,132.66,130.36,128.57,128.53,128.49,128.04,127.90,127.85,127.76,123.05,97.68,77.52,76.24,74.27,73.69,73.60,70.94,and68.50.IR(thin film,cm-1):3029,3006,2989,2862,1275,1260,1090,1043,1025,764,750,and695cm-1.HRMS(DART-TOF)calculated for C32H32NO4 +[M+H]+m/z 494.2326,found494.2325.
(25)1- (quinolin-6-yl) -3,4, 6-tribenzyloxy-D-glucal ene (13x)
Figure BDA0002023477080000281
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), quinoline-6-boronic acid (0.40mmol,69.2mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give compound 13x (96.7mg,0.18mmol, 89% yield) as a white solid.1H NMR(CDCl3,400MHz):8.87(dd,J＝4.0,1.6Hz,1H),8.11(dd,J＝8.4,1.6Hz,1H),8.07(d,J＝2.0Hz,1H),8.05(d,J＝8.8Hz,1H),7.90(dd,J＝9.2,2.0Hz,1H),7.39–7.25(m,16H),5.61(d,J＝3.2Hz,1H),4.87(d,J＝11.2Hz,1H),4.73(d,J＝11.2Hz,1H),4.70(d,J＝11.6Hz,1H),4.66(d,J＝11.6Hz,1H),4.65(d,J＝12.0Hz,1H),4.62(d,J＝12.0Hz,1H),4.42(dd,J＝5.9,3.2Hz,1H),4.34(ddd,J＝8.0,4.9,3.0Hz,1H),4.02(dd,J＝8.3,5.9Hz,1H),3.97(dd,J＝10.9,5.0Hz,1H),and3.92(dd,J＝10.9,3.1Hz,1H).13C NMR(CDCl3,101MHz):151.90,150.68,148.47,138.49,138.28,138.26,136.59,132.50,129.26,128.55,128.51,128.47,128.03,127.86,127.84,127.80,127.76,127.72,126.74,124.41,121.53,97.74,77.49,76.48,74.41,73.62,73.53,70.80,and68.62.IR(thinfilm,cm-1):3031,2865,1264,1091,1027,764,731,and 697cm-1.HRMS(DART-TOF)calculated for C36H34NO4 +[M+H]+m/z 544.2482, found 544.2484, melting point 106.7-108.9 ℃.
(26)1- (quinolin-3-yl) -3,4, 6-tribenzyloxy-D-glucal ene (13y)
Figure BDA0002023477080000282
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), quinoline-3-boronic acid (0.40mmol,102.1mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4(0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg)The mixture of tetrahydrofuran (1.0mL) solution was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give compound 13y (94.5mg,0.17mmol, 87% yield) as a white solid.1H NMR(CDCl3,400MHz):9.10(d,J＝2.4Hz,1H),8.33(d,J＝1.6Hz,1H),8.09(d,J＝8.4Hz,1H),7.80(dd,J＝8.0,1.3Hz,1H),7.68(ddd,J＝8.4,6.4,1.2Hz,1H),7.53(ddd,J＝8.4,6.4,1.2Hz,1H),7.40–7.25(m,15H),5.63(d,J＝3.2Hz,1H),4.88(d,J＝11.2Hz,1H),4.75(d,J＝11.6Hz,1H),4.72(d,J＝12.0Hz,1H),4.68(d,J＝11.6Hz,1H),4.64(d,J＝12.0Hz,1H),4.63(d,J＝12.0Hz,1H),4.41(dd,J＝6.0,3.2Hz,1H),4.35(ddd,J＝8.4,4.8,3.2Hz,1H),4.03(dd,J＝8.4,6.0Hz,1H),3.96(dd,J＝10.9,5.0Hz,1H),and3.91(dd,J＝10.9,3.0Hz,1H).13C NMR(CDCl3,101MHz):150.41,147.96,147.89,138.40,138.20,132.08,129.78,129.29,128.59,128.53,128.49,128.38,128.05,127.90,127.88,127.88,127.77,127.77,127.54,127.39,127.05,98.14,77.53,76.28,74.31,73.68,73.58,71.04,and68.51.IR(thin film,cm-1):3029,2861,1650,1495,1452,1361,1291,1090,1025,788,748,733,and 695cm-1.HRMS(DART-TOF)calculated for C36H34NO4 +[M+H]+m/z 544.2482, found 544.2482 melting point 106.3-109.5 ℃.
(27)1- (N-phenylindol-5-yl) -3,4, 6-tribenzyloxy-D-glucal (13z)
Figure BDA0002023477080000283
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), N-phenylindole-5-boronic acid (0.40mmol,133.3mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded compound 13z (84.6mg,0.14mmol, 68% yield) as a colorless oil.1H NMR(CDCl3,400MHz):7.94(d,J＝1.6Hz,1H),7.43(dd,J＝8.7,1.7Hz,1H),7.39–7.23(m,18H),7.19(d,J＝8.7Hz,1H),7.09(d,J＝3.2Hz,1H),7.05(dd,J＝7.8,1.7Hz,2H),6.54(d,J＝3.1Hz,1H),5.39(d,J＝3.1Hz,1H),5.27(s,2H),4.87(d,J＝11.6Hz,1H),4.73(d,J＝11.6Hz,1H),4.70(d,J＝11.6Hz,1H),4.68(d,J＝12.0Hz,1H),4.63(d,J＝11.6Hz,1H),4.62(d,J＝12.0Hz,1H),4.42(dd,J＝6.0,3.1Hz,1H),4.28(ddd,J＝8.1,4.7,3.0Hz,1H),4.00(dd,J＝8.5,6.0Hz,1H),3.96(dd,J＝11.0,4.9Hz,1H),and3.92(dd,J＝11.0,2.9Hz,1H).13C NMR(CDCl3,101MHz):154.20,138.86,138.55,137.50,136.75,128.96,128.87,128.60,128.51,128.48,128.45,128.05,127.85,127.79,127.76,127.74,127.65,127.61,126.81,126.52,119.79,118.57,109.42,102.55,94.47,77.48,77.16,74.81,73.59,73.58,70.31,68.96,and50.27.IR(thin film,cm-1):3062,2920,2856,1648,1452,1094,1027,731,and 696cm-1.HRMS(DART-TOF)calculated forC42H40NO4 +[M+H]+m/z 622.2952,found 622.2956.
(28)1- (1-phenyl-1H-pyrrolo [2,3-b ] pyridin-5-yl) -3,4, 6-tribenzyloxy-D-glucal (13aa)
Figure BDA0002023477080000291
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), 1-phenyl-1H-pyrrole [2, 3-b), prepared in example 1 according to standard procedures]Pyridine-5-boronic acid (0.40mmol,133.7mg), Ni (COD)2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded compound 13aa (107.1mg,0.17mmol, yield 86%) as a colorless oil.1H NMR(CDCl3,400MHz):8.62(d,J＝2.0Hz,1H),8.13(d,J＝2.1Hz,1H),7.38–7.23(m,18H),7.20–7.16(m,2H),7.15(d,J＝3.5Hz,1H),6.47(d,J＝3.5Hz,1H),5.47(s,2H),5.42(d,J＝3.2Hz,1H),4.87(d,J＝11.2Hz,1H),4.73(d,J＝11.2Hz,1H),4.70(d,J＝11.6Hz,1H),4.67(d,J＝11.6Hz,1H),4.64(d,J＝11.6Hz,1H),4.61(d,J＝11.6Hz,1H),4.41(dd,J＝6.0,3.2Hz,1H),4.31(ddd,J＝8.0,4.9,2.9Hz,1H),4.01(dd,J＝8.4,5.9Hz,1H),3.96(dd,J＝11.0,4.9Hz,1H),and3.90(dd,J＝11.0,2.9Hz,1H).13C NMR(CDCl3,101MHz):152.33,147.98,141.39,138.64,138.41,138.38,137.77,128.81,128.70,128.56,128.52,128.48,128.06,127.89,127.84,127.80,127.76,127.73,127.69,127.53,126.17,123.37,119.85,100.81,95.39,77.53,76.74,74.59,73.65,73.63,70.62,68.78,and48.07.IR(thin film,cm-1):3029,2927,2862,1275,1261,1086,1026,906,764,749,729,and 695cm-1.HRMS(DART-TOF)calculated for C41H39N2O4 +[M+H]+m/z 623.2904,found 623.2911.
(29)1- (5-methoxypyridin-3-yl) -3,4, 6-tribenzyloxy-D-glucal (13ab)
Figure BDA0002023477080000292
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), 5-methoxypyridine-3-boronic acid pinacol ester (0.40mmol,61.2mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded 13ab (88.0mg,0.17mmol, 84% yield) as a colorless oily compound.1H NMR(CDCl3,400MHz):8.45(d,J＝1.6Hz,1H),8.24(d,J＝2.8Hz,1H),7.37–7.36(m,1H),7.36–7.27(m,15H),5.47(d,J＝3.2Hz,1H),4.85(d,J＝11.2Hz,1H),4.72(d,J＝11.6Hz,1H),4.69(d,J＝12.0Hz,1H),4.65(d,J＝11.6Hz,1H),4.62(d,J＝12.4Hz,1H),4.58(d,J＝12.0Hz,1H),4.35(dd,J＝6.0,3.2Hz,1H),4.29(ddd,J＝8.4,4.8,2.8Hz,1H),3.97(dd,J＝8.4,6.0Hz,1H),3.91(dd,J＝10.9,5.0Hz,1H),3.86(dd,J＝10.9,3.0Hz,1H),and3.83(s,3H).13C NMR(CDCl3,101MHz):155.49,150.19,139.32,138.40,138.21,138.20,137.64,131.13,128.59,128.55,128.50,128.06,127.92,127.88,127.77,127.74,117.12,98.06,77.52,76.17,74.28,73.67,73.59,70.99,68.49,and55.70.IR(thin film,cm-1):3028,3006,2863,1453,1275,1260,1204,1089,1026,764,749,and 695cm-1.HRMS(DART-TOF)calculated for C33H34NO5 +[M+H]+m/z 524.2431,found524.2434.
(30)1- (6-methoxypyridin-3-yl) -3,4, 6-tribenzyloxy-D-glucal (13ac)
Figure BDA0002023477080000301
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), 6-methoxypyridine-3-boronic acid pinacol ester (0.40mmol,61.2mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded compound 13ac (94.3mg,0.18mmol, yield 90%) as a colorless oil.1H NMR(CDCl3,400MHz):8.42(d,J＝2.4Hz,1H),7.74(dd,J＝8.7,2.5Hz,1H),7.36–7.26(m,15H),6.69(d,J＝8.7Hz,1H),5.30(d,J＝3.1Hz,1H),4.85(d,J＝11.2Hz,1H),4.71(d,J＝11.2Hz,1H),4.68(d,J＝11.6Hz,1H),4.64(d,J＝11.6Hz,1H),4.61(d,J＝12.4Hz,1H),4.58(d,J＝12.4Hz,1H),4.35(dd,J＝5.9,3.1Hz,1H),4.26(ddd,J＝8.0,4.9,2.9Hz,1H),3.96(dd,J＝8.4,6.0Hz,1H),3.94(s,3H),3.90(dd,J＝10.9,2.9Hz,1H),and3.85(dd,J＝10.9,2.9Hz,1H).13C NMR(CDCl3,101MHz):164.44,150.84,144.37,138.53,138.31,138.29,135.88,128.58,128.54,128.50,128.08,127.89,127.88,127.82,127.79,127.74,123.99,110.30,95.52,77.47,76.46,74.41,73.67,73.66,70.78,68.65,and53.71.IR(thin film,cm-1):3029,2861,1601,1493,1453,1379,1284,1091,1023,831,748,733,and 696cm-1.HRMS(DART-TOF)calculated for C33H34NO5 +[M+H]+m/z524.2431,found 524.2434.
(31)1- (6-trifluoromethylpyridin-3-yl) -3,4, 6-tribenzyloxy-D-glucal (13ad)
Figure BDA0002023477080000302
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), 6-trifluoromethylpyridine-3-boronic acid (0.40mmol,76.4mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give 13ad (105.5mg,0.19mmol, 94% yield) as a white solid.1H NMR(CDCl3,400MHz):8.90(d,J＝2.0Hz,1H),8.00(dd,J＝8.4,2.0Hz,1H),7.63(d,J＝8.0Hz,1H),7.37–7.27(m,15H),5.55(d,J＝3.2Hz,1H),4.85(d,J＝11.6Hz,1H),4.72(d,J＝11.6Hz,1H),4.69(d,J＝12.0Hz,1H),4.65(d,J＝12.0Hz,1H),4.60(d,J＝12.0Hz,1H),4.59(d,J＝12.0Hz,1H),4.35(dd,J＝6.0,3.2Hz,1H),4.31(ddd,J＝8.4,4.8,2.8Hz,1H),3.98(dd,J＝8.4,6.0Hz,1H),3.91(dd,J＝10.9,5.0Hz,1H),and3.85(dd,J＝10.9,2.9Hz,1H).13C NMR(CDCl3,101MHz):149.09,147.75(q,J＝34.8Hz),146.99,138.22,138.08,133.82,133.09,128.65,128.59,128.54,128.07,128.00,127.91,127.86,127.80,121.64(q,J＝275.2Hz),120.00(q,J＝6.0Hz),99.83,77.65,75.96,74.09,73.77,73.65,71.31,and68.36.19F NMR(CDCl3,376MHz):–67.83.IR(thin film,cm-1):3029,3006,2989,2865,1334,1275,1260,1085,1025,764,749,and695cm-1.HRMS(DART-TOF)calculated for C33H31F3NO4 +[M+H]+m/z 562.2200, found562.2208, melting point 73.2-75.1 ℃.
(32)1- (6-Morpholinpyridin-3-yl) -3,4, 6-tribenzyloxy-D-glucal ene (13ae)
Figure BDA0002023477080000311
alpha-O-alkenylsulfone 8a (0.20mmol,111mg), 6-morpholinopyridine-3-boronic acid (0.40mmol,83.2mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4(0.04mmol,14.7mg) was mixed with a solution of KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL)The mixture was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give 13ae (102.9mg,0.18mmol, 89% yield) as a colorless oily compound.1H NMR(CDCl3,400MHz):8.45(d,J＝2.0Hz,1H),7.68(dd,J＝8.6,2.4Hz,1H),7.35–7.26(m,15H),6.56(d,J＝9.2Hz,1H),5.26(d,J＝3.2Hz,1H),4.85(d,J＝11.2Hz,1H),4.71(d,J＝11.2Hz,1H),4.67(d,J＝12.0Hz,1H),4.64(d,J＝12.0Hz,1H),4.61(d,J＝12.0Hz,1H),4.60(d,J＝12.0Hz,1H),4.36(dd,J＝6.0,3.2Hz,1H),4.24(ddd,J＝8.0,4.8,2.8Hz,1H),3.96(dd,J＝8.4,6.0Hz,1H),3.91(dd,J＝10.9,4.9Hz,1H),3.85(dd,J＝11.0,2.9Hz,1H),3.82–3.78(m,4H),and3.55–3.50(m,4H).13C NMR(CDCl3,101MHz):159.46,151.28,145.51,138.62,138.36,134.72,128.55,128.52,128.48,128.07,127.86,127.77,127.70,120.60,105.89,94.19,77.38,76.62,74.52,73.66,73.61,70.64,68.74,66.80,and45.62.IR(thin film,cm-1):3449,3005,2856,1595,1496,1275,1260,1238,1112,1068,1026,942,764,749,and 696cm-1.HRMS(DART-TOF)calculated forC36H39N2O5 +[M+H]+m/z 579.2853,found 579.2862.
(33)1- (6- (4-tert-Butoxycarbonylpiperazin-1-yl) pyridin-3-yl) -3,4, 6-tribenzyloxy-D-glucal (13af)
Figure BDA0002023477080000312
alpha-O-alkenylsulfone 8a (0.20mmol,111mg),6- (4-tert-butoxycarbonylpiperazin-1-yl) pyridine-3-boronic acid pinacol ester (0.40mmol,122.9mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give 13af (108.4mg,0.16mmol, 80% yield) as a colorless oily compound.1H NMR(CDCl3,400MHz):8.44(d,J＝2.4Hz,1H),7.67(dd,J＝8.9,2.4Hz,1H),7.39–7.26(m,15H),6.57(d,J＝8.9Hz,1H),5.26(d,J＝3.1Hz,1H),4.85(d,J＝11.6Hz,1H),4.71(d,J＝11.6Hz,1H),4.67(d,J＝11.6Hz,1H),4.63(d,J＝12.0Hz,1H),4.62(d,J＝11.6Hz,1H),4.59(d,J＝12.0Hz,1H),4.35(dd,J＝5.9,3.2Hz,1H),4.24(ddd,J＝8.0,4.9,3.0Hz,1H),3.95(dd,J＝8.3,5.8Hz,1H),3.91(dd,J＝11.0,4.9Hz,1H),3.85(dd,J＝11.0,3.0Hz,1H),3.58–3.50(m,8H),and1.48(s,9H).13C NMR(CDCl3,101MHz):159.12,154.91,151.26,145.52,143.75,138.60,138.34,134.76,128.53,128.51,128.46,128.05,127.85,127.75,127.68,120.39,106.11,94.13,80.09,77.36,76.60,74.51,73.64,73.59,70.62,68.72,45.08,28.55,and24.93.IR(thin film,cm-1):3461,2977,2861,1691,1594,1407,1364,1236,1164,996,931,749,733,and 697cm-1.HRMS(DART-TOF)calculated for C41H48N3O6 +[M+H]+m/z 678.3538,found 678.3544.
(34)1- (2, 4-Dimethoxypyrimidin-5-yl) -3,4, 6-tribenzyloxy-D-glucal ene (13ag)
Figure BDA0002023477080000321
alpha-O-alkenylsulfone 8a (0.20mmol,111mg),2, 4-dimethoxypyrimidine-5-boronic acid (0.40mmol,73.6mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification gave compound 13ag (79.5mg,0.15mmol, 73% yield) as a colorless oil.1H NMR(CDCl3,400MHz):8.56(s,1H),7.36–7.25(m,15H),5.71(d,J＝3.2Hz,1H),4.86(d,J＝11.6Hz,1H),4.71(d,J＝11.6Hz,1H),4.67(d,J＝12.0Hz,1H),4.64(d,J＝12.0Hz,1H),4.61(d,J＝12.0Hz,1H),4.58(d,J＝12.0Hz,1H),4.38(dd,J＝6.4,3.2Hz,1H),4.20(ddd,J＝8.0,4.8,2.8Hz,1H),4.01(s,3H),4.00(s,3H),3.97(dd,J＝8.4,6.4Hz,1H),3.90(dd,J＝10.9,4.7Hz,1H)and3.84(dd,J＝11.0,2.8Hz,1H).13C NMR(CDCl3,101MHz):167.83,164.47,157.36,146.42,138.59,138.32,138.23,128.49,128.47,128.04,127.85,127.83,127.74,127.71,109.95,101.07,77.41,76.97,74.23,73.69,73.62,70.62,68.63,54.99,and54.26.IR(thin film,cm-1):3006,2989,2864,1590,1556,1470,1400,1276,1260,1076,1011,803,764,749,and 696cm-1.HRMS(DART-TOF)calculatedfor C33H35N2O6 +[M+H]+m/z 555.2490,found 555.2491.
(35)1- (11- (1-ethoxycarbonylpiperidin-4-ylalkenyl) -6, 11-dihydro-5H-benzo [5,6] cyclohepta [1,2-b ] pyridin-8-yl) -3,4, 6-tribenzyloxy-D-glucal (13ah)
Figure BDA0002023477080000322
alpha-O-alkenylsulfone 8a (0.20mmol,111mg),11- (1-ethoxycarbonylpiperidin-4-ylalkenyl) -6, 11-dihydro-5H-benzo [5,6] prepared in example 1 according to standard procedures]Cyclohepta [1,2-b ]]Pyridine-8-boronic acid (0.40mmol,189.7mg), Ni (COD)2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded compound 13ah (83.9mg,0.11mmol, yield 55%) as a colorless oil.1HNMR(CDCl3,400MHz):8.39(dd,J＝4.8,1.7Hz,1H),7.44–7.38(m,3H),7.37–7.25(m,15H),7.16(d,J＝7.9Hz,1H),7.07(dd,J＝7.7,4.8Hz,1H),5.40(d,J＝3.1Hz,1H),4.84(d,J＝11.6Hz,1H),4.71(d,J＝11.6Hz,1H),4.68(d,J＝12.0Hz,1H),4.64(d,J＝12.0Hz,1H),4.62(d,J＝12.4Hz,1H),4.59(d,J＝12.4Hz,1H),4.34–4.39(m,1H),4.27–4.21(m,1H),4.13(q,J＝7.1Hz,2H),3.95(dd,J＝8.4,5.9Hz,1H),3.92–3.85(m,2H),3.84–3.74(m,2H),3.47–3.30(m,2H),3.19–3.09(m,2H),2.90–2.78(m,2H),2.55–2.45(m,1H),2.40–2.28(m,3H),and1.25(t,J＝7.1Hz,3H).13C NMR(CDCl3,101MHz):157.42,157.31,155.62,152.61,152.56,146.68,139.94,139.84,138.63,138.39,138.37,137.64,137.59,137.53,137.11,135.13,133.80,133.71,129.27,129.21,128.52,128.48,128.44,127.99,127.81,127.73,127.66,126.04,126.02,123.20,123.17,122.23,96.09,96.04,77.42,76.65,76.61,74.53,73.57,73.53,70.56,70.53,68.74,61.39,44.98,32.04,32.01,31.91,31.85,30.90,30.66,and14.81.IR(thin film,cm-1):3032,2917,2861,1689,1264,1228,1111,1097,908,729,and 697cm-1.HRMS(DART-TOF)calculated for C49H51N2O6 +[M+H]+m/z763.3742,found 763.3745.
(36) 1-phenyl-3, 4, 6-tri-tert-butyldimethylsilyloxy-D-glucal-ene (16a)
Figure BDA0002023477080000331
alpha-O-alkenylsulfone 15a prepared in example 1 (0.15mmol,94.3mg), phenylboronic acid (0.30mmol,36.6mg), Ni (COD) according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification gave compound 16a (69.5mg,0.12mmol, yield 82%) as a colorless oil.1H NMR(CDCl3,400MHz):7.65–7.61(m,2H),7.36–7.30(m,3H),5.28(d,J＝4.0Hz,1H),4.20–4.16(m,2H),4.00(dd,J＝11.2,7.0Hz,1H),3.92–3.85(m,2H),0.93(s,9H),0.91(s,9H),0.90(s,9H),0.15(s,6H),0.14(s,6H),0.06(s,3H),and0.03(s,3H).13C NMR(CDCl3,101MHz):150.81,135.72,128.50,128.18,125.44,98.16,80.67,70.52,69.17,61.78,26.15,26.10,26.06,18.53,18.30,18.27,-3.79,-3.89,-3.99,-4.49,-5.10,and-5.15.IR(thin film,cm-1):2954,2929,2886,2857,1472,1462,1256,1104,1081,833,772,and 750cm-1.HRMS(DART-TOF)calculated for C39H34NaO5 +[M+Na]+m/z 587.3379,found587.3384.
(37) 1-phenyl-3-O-triisopropylsiloxy-4, 6-O-di-tert-butylsilyl-D-glucal (16b)
Figure BDA0002023477080000332
In accordance with standard practice of the process,α -O-alkenylsulfone prepared in example 1 (0.10mmol,58.3mg), phenylboronic acid (0.20mmol,24.4mg), Ni (COD)2(0.01mmol,2.8mg),Cy3PHBF4A mixture of (0.02mmol,7.4mg), and KOH (0.20mmol,11.2mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded compound 16b as a colorless oil (31.2mg,0.06mmol, yield 60%).1H NMR(CDCl3,400MHz):7.54–7.49(m,2H),7.35–7.29(m,3H),5.23(d,J＝2.3Hz,1H),4.59(dd,J＝6.7,2.4Hz,1H),4.32(dd,J＝10.4,4.8Hz,1H),4.12(dd,J＝10.0,1.2Hz,1H),4.09(dd,J＝9.6,2.8Hz,1H),3.99(ddd,J＝10.1,4.8,2.8Hz,1H),1.18–1.12(m,21H),1.08(s,9H),and1.01(s,9H).13C NMR(CDCl3,101MHz):151.17,134.35,128.77,128.34,125.20,101.42,77.68,73.16,71.92,66.29,27.63,27.13,22.93,20.05,18.37,18.35,and12.68.IR(thin film,cm-1):2933,2862,1654,1470,1339,1279,1260,1161,1110,1086,1021,889,825,760,and 752cm-1.HRMS(DART-TOF)calculated for C29H50NaO4Si2 +[M+Na]+m/z 541.3140,found 541.3141.
(38) 1-phenyl-3, 4, 6-tribenzyloxy-D-galactan (16c)
Figure BDA0002023477080000333
alpha-O-alkenylsulfone prepared in example 1 (0.15mmol,83.4mg), phenylboronic acid (0.30mmol,36.6mg), Ni (COD) according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification gave compound 16c (53.2mg,0.11mmol, yield 72%) as a colorless oil.1H NMR(CDCl3,400MHz):7.62–7.57(m,2H),7.37–7.23(m,18H),5.41(dd,J＝3.2,0.8Hz,1H),4.88(d,J＝12.0Hz,1H),4.71–4.66(m,3H),4.52(d,J＝12.0Hz,1H),4.48(d,J＝12.0Hz,1H),4.37–4.41(m,1H),4.35–4.31(m,1H),4.06–4.03(m,1H),3.90(dd,J＝10.4,5.6Hz,1H),and3.82(dd,J＝10.4,5.6Hz,1H).13C NMR(CDCl3,101MHz):151.96,138.73,138.60,138.30,134.83,128.67,128.51,128.50,128.41,128.17,127.92,127.77,127.74,127.67,127.62,125.34,96.29,76.24,73.53,73.30,71.82,71.28,71.23,and68.48.IR(thin film,cm-1):3061,3028,2922,2859,1451,1275,1260,1083,1026,764,749,and694cm-1.HRMS(DART-TOF)calculated for C33H32NaO4 +[M+Na]+m/z 515.2193,found515.2200.
(39) 1-phenyl-3, 4-dibenzyloxy-D-fucosylene (16D)
Figure BDA0002023477080000341
alpha-O-alkenylsulfone prepared in example 1, 15d (0.15mmol,67.5mg), phenylboronic acid (0.30mmol,36.6mg), Ni (COD) according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification gave compound 16d (40.6mg,0.11mmol, yield 70%) as a colorless oil.1H NMR(CDCl3,400MHz):7.64–7.57(m,2H),7.43–7.24(m,13H),5.40(dd,J＝2.8,1.2Hz,1H),4.96(d,J＝12.0Hz,1H),4.76(d,J＝12.0Hz,1H),4.74(d,J＝12.0Hz,1H),4.71(d,J＝12.0Hz,1H),4.40(ddd,J＝4.3,3.0,1.2Hz,1H),4.25(qdd,J＝6.7,2.0,1.1Hz,1H),3.78(ddd,J＝4.4,2.0,1.2Hz,1H),and1.41(d,J＝6.4Hz,3H).13C NMR(CDCl3,101MHz):152.43,138.86,138.79,135.14,128.55,128.37,128.35,128.16,127.70,127.65,125.30,95.75,73.55,73.30,73.09,71.16,and16.61.IR(thin film,cm-1):3028,2929,2853,1495,1450,1276,1261,1100,1063,1025,765,749,730,and 693cm-1.HRMS(DART-TOF)calculatedfor C26H26NaO3 +[M+Na]+m/z 409.1774,found 409.1781.
(40) 1-phenyl-3, 4-dibenzyloxy-L-rhamnosene (16e)
Figure BDA0002023477080000342
alpha-O-alkenylsulfone 15e (0.15mmol,67.5mg), phenylboronic acid (0.30mmol,36.6mg), Ni (COD) prepared in example 1 according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent to give compound 16e (49.8mg,0.13mmol, 86% yield) as a white solid.1H NMR(CDCl3,400MHz):7.60–7.55(m,2H),7.41–7.27(m,13H),5.42(d,J＝2.8Hz,1H),4.91(d,J＝11.6Hz,1H),4.74(d,J＝11.6Hz,1H),4.73(d,J＝11.6Hz,1H),4.66(d,J＝11.6Hz,1H),4.40(dd,J＝6.5,2.8Hz,1H),4.13(dq,J＝9.0,6.4Hz,1H),3.59(dd,J＝9.1,6.5Hz,1H),and1.50(d,J＝6.4Hz,3H).13C NMR(CDCl3,101MHz):153.08,138.71,138.46,134.73,128.76,128.56,128.54,128.26,128.12,127.90,127.88,127.76,125.31,96.41,79.74,77.70,74.54,74.07,70.68,and17.74.IR(thin film,cm-1):3028,3005,2989,2931,2862,1276,1260,1099,1063,764,750,and 694cm-1.HRMS(DART-TOF)calculated for C26H26NaO3 +[M+Na]+m/z 409.1774, found 409.1778 melting point 73.5-74.9 deg.C
(41) 1-phenyl-3, 4-dibenzyloxy-D-arabinoxene (16f)
Figure BDA0002023477080000343
alpha-O-alkenylsulfone prepared in example 1 (0.15mmol,65.4mg), phenylboronic acid (0.30mmol,36.6mg), Ni (COD) according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in t-butanol (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded compound 16f as a colorless oil (43.0mg,0.12mmol, yield 77%).1H NMR(CDCl3,400MHz):7.57–7.53(m,2H),7.43–7.27(m,13H),5.43(d,J＝5.2Hz,1H),4.77(s,2H),4.72(d,J＝12.0Hz,1H),4.65(d,J＝12.4Hz,1H),4.27(dd,J＝10.4,10.4Hz,1H),4.21–4.16(m,2H),and3.84(ddd,J＝10.4,3.8,3.8Hz,1H).13C NMR(CDCl3,101MHz):154.38,139.04,138.24,134.82,128.93,128.58,128.50,128.27,128.01,127.93,127.89,127.68,125.40,95.02,73.38,71.27,71.14,67.82,and63.91.IR(thinfilm,cm-1):3027,3005,2988,2927,2854,1275,1260,1088,1026,764,749,and 693cm- 1.HRMS(DART-TOF)calculated for C25H24NaO3 +[M+Na]+m/z 395.1618,found 395.1624.
(42) 1-phenyl-3, 4-dibenzyloxy-D-xylosene (16g)
Figure BDA0002023477080000351
According to standard procedures, 15g (0.15mmol,65.4mg) of the α -O-alkenylsulfone prepared in example 1, phenylboronic acid (0.30mmol,36.6mg), Ni (COD)2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed, and the eluent was petroleum ether/ethyl acetate 10:1, to separate and purify 16g (46.3mg,0.12mmol, 83% yield) of the compound as a colorless oil.1H NMR(CDCl3,400MHz):7.65–7.59(m,2H),7.38–7.26(m,13H),5.49(dd,J＝4.8,1.2Hz,1H),4.69(d,J＝12.4Hz,1H),4.67(d,J＝12.4Hz,1H),4.65(d,J＝12.0Hz,1H),4.59(d,J＝12.0Hz,1H),4.32(ddd,J＝12.0,4.8,1.2Hz,1H),4.15(dd,J＝11.6,2.0Hz,1H),4.06(ddd,J＝4.8,3.2,1.2Hz,1H),and3.78–3.74(m,1H).13C NMR(CDCl3,101MHz):154.38,138.63,138.19,135.05,128.85,128.61,128.58,128.23,127.95,127.91,127.87,127.81,125.40,95.14,72.85,71.34,71.00,70.34,and64.85.IR(thin film,cm-1):3028,3006,2988,2924,2863,1451,1276,1260,1095,1055,1026,764,749,and 693cm-1.HRMS(DART-TOF)calculated for C25H24NaO3 +[M+Na]+m/z 395.1618,found 395.1620.
(43) 1-phenyl-hexabenzyloxy-D-malto-ene (16h)
Figure BDA0002023477080000352
alpha-O-alkenylsulfone prepared in example 1, 15h (0.10mmol,98.8mg), phenylboronic acid (0.20mmol,24.4mg), Ni (COD) according to standard procedures2(0.02mmol,5.5mg),Cy3PHBF4A mixture of (0.04mmol,14.7mg), and KOH (0.40mmol,22.4mg) in tetrahydrofuran (1.0mL) was stirred at 60 ℃ for 12 hours. Column chromatography was performed with petroleum ether/ethyl acetate 10:1 as eluent, and separation and purification yielded compound 16h (85.1mg,0.09mmol, 92%) as colorless oil.1H NMR(CDCl3,400MHz):7.63–7.57(m,2H),7.35–7.22(m,31H),7.12(m,2H),5.55(d,J＝3.6Hz,1H),5.44(d,J＝3.6Hz,1H),4.93(d,J＝10.8Hz,1H),4.80(d,J＝10.8Hz,1H),4.78(d,J＝10.8Hz,1H),4.66(d,J＝11.2Hz,1H),4.65(s,2H),4.57(s,1H),4.56(d,J＝12Hz,1H),4.53(d,J＝11.6Hz,1H),4.47(d,J＝10.8Hz,1H),4.48–4.40(m,2H),4.35(d,J＝12Hz,1H),4.32(dd,J＝7.2,5.2Hz,1H),3.95(dd,J＝11.2,5.2Hz,1H),3.92(dd,J＝9.6,8.8Hz,1H),3.91-3.86(m,1H),3.85(dd,J＝11.2,3.6Hz,1H),3.67(dd,J＝10.0,9.2Hz,1H),3.61(dd,J＝10.8,2.8Hz,1H,H6b),3.57(dd,J＝9.6,3.6Hz,1H),and3.49(dd,J＝10.8,2.0Hz,1H,H6a).13C NMR(CDCl3,101MHz):153.23,139.05,138.61,138.58,138.45,138.28,138.14,134.65,128.90,128.55,128.50,128.45,128.43,128.40,128.30,128.07,128.02,127.99,127.98,127.84,127.73,127.72,127.70,127.67,127.61,127.60,127.59,125.37,96.21,95.73,81.99,79.82,77.75,77.22,76.17,75.70,75.11,73.57,73.52,72.89,70.94,70.13,68.98,68.45,and68.41.IR(thin film,cm-1):3028,3006,2989,2862,1452,1275,1260,1068,1027,764,749,and 695cm-1.HRMS(DART-TOF)calculated for C60H60NaO9 +[M+Na]+m/z 947.4130,found 947.4128.
When the starting alpha-O-alkenylsulfone is a mixture of two isomers of E/Z, the reaction results in the same product when either the E or Z isomer alone is used.
(44)1- (1-methoxy-2-styryl) -4-methylbenzene (21a)
Figure BDA0002023477080000361
With reference to standard procedures, α -O-alkenylsulfone 19a (0.30mmol,82.3mg,1.0equiv), p-tolylboronic acid (0.60mmol,81.6mg,2.0equiv), Ni (COD) prepared in example 12(0.03mmol,8.25mg,0.1equiv),Cy3PHBF4A mixture of (0.06mmol,22.0mg,0.2equiv), and KOH (0.60mmol,33.6mg,2.0equiv) was stirred in tetrahydrofuran (1.5mL) at 60 ℃ for 8 hours. Column chromatography was performed with petroleum ether/ethyl acetate 25:1 as eluent to give compound 21a (56mg,0.25mmol, 83% yield, a mixture of the two inseparable isomers E and Z) as a colorless oil.1H NMR(CDCl3,400MHz):7.72–7.66(m,1.32H),7.47–7.41(m,1.32H),7.33(t,J＝7.6Hz,1.36H),7.26–7.16(m,2.40H),7.13–6.95(m,2.60H),6.05(s,0.64H,E-isomer),5.78(s,0.36H,Z-isomer),3.77(s,1.08H,Z-isomer),3.61(d,J＝1.0Hz,1.92H,E-isomer),2.37(s,1.92H,E-isomer),and2.31(s,1.08H,Z-isomer).13C NMR(CDCl3,101MHz):157.47,156.51,138.52,138.41,137.24,136.20,133.64,133.44,129.31,129.29,129.01,128.95,128.66,128.48,128.06,126.68,126.52,125.24,112.18,101.33,57.98,55.57,21.47,and21.38.IR(thin film,cm-1):3021,2933,2835,1631,1510,1446,1276,1199,1119,1063,819,764,750,and 694cm-1.HRMS(DART-TOF)calculated for C16H16NaO+[M+Na]+m/z 247.1093,found 247.1098.
(45)1- (1-methoxy-4-methylpentyl-1-enyl) -4-methylbenzene (21b)
Figure BDA0002023477080000362
With reference to standard procedures, α -O-alkenylsulfone 19b (0.30mmol,76.2mg,1.0equiv), p-tolylboronic acid (0.60mmol,81.6mg,2.0equiv), Ni (COD) prepared in example 12(0.03mmol,8.25mg,0.1equiv),Cy3PHBF4(0.06mmol,22.0mg,0.2equiv), and KOH (0.60mmol,33.6mg,2.0equiv)The mixture was stirred in tetrahydrofuran (1.5mL) at 60 ℃ for 8 hours. Column chromatography was performed with petroleum ether/ethyl acetate 25:1 as eluent to give compound 21b (43mg,0.21mmol, 70% yield) as a colorless oil.1H NMR(CDCl3,400MHz):7.37–7.32(m,1.5H),7.26–7.23(m,0.5H),7.17–7.12(m,2.0H),5.26(t,J＝7.2Hz,0.74H,E-isomer),4.71(t,J＝7.2Hz,0.26H,Z-isomer),3.62(s,0.78H,Z-isomer),3.50(s,2.22H,E-isomer),2.34(s,3H),2.15(t,J＝7.2Hz,1.48H,E-isomer),1.95(t,J＝7.1Hz,0.52H,Z-isomer),1.69(hept,J＝6.7Hz,0.74H,E-isomer),1.59(hept,J＝6.7Hz,0.26H,Z-isomer),0.95(d,J＝6.7Hz,4.44H,E-isomer),and0.87(d,J＝6.7Hz,1.56H,Z-isomer).13C NMR(CDCl3,101MHz):155.77,155.19,137.71,137.55,133.87,133.44,129.16,128.80,128.72,126.01,112.87,99.14,58.49,55.09,36.53,34.68,29.90,28.96,22.66,22.42,21.41,and21.29.IR(thin film,cm-1):2953,2868,1275,1260,1118,1078,822,764,and 750cm-1.HRMS(DART-TOF)calculated for C14H20NaO+[M+Na]+m/z 227.1406,found227.1411.
(46)1- (1-methoxy-5-triisopropylsiloxy-1-enyl) -4-methylbenzene (21c)
Figure BDA0002023477080000363
With reference to standard procedures, α -O-alkenylsulfone 19c (0.30mmol,124mg,1.0equiv), p-tolylboronic acid (0.60mmol,81.6mg,2.0equiv), Ni (COD) prepared in example 12(0.03mmol,8.25mg,0.1equiv),Cy3PHBF4A mixture of (0.06mmol,22.0mg,0.2equiv), and KOH (0.60mmol,33.6mg,2.0equiv) was stirred in tetrahydrofuran (1.5mL) at 60 ℃ for 8 hours. Column chromatography was performed with petroleum ether/ethyl acetate 25:1 as eluent to give compound 21c as a colorless oil (98mg,0.27mmol, 90% yield).1H NMR(CDCl3,400MHz):7.36–7.30(m,1.3H),7.28–7.24(m,0.7H),7.16–7.11(m,2H),5.28(t,J＝7.2Hz,0.62H,E-isomer),4.70(t,J＝7.2Hz,0.38H,Z-isomer),3.75(t,J＝6.5Hz,1.24H,E-isomer),3.66(t,J＝6.5Hz,0.76H,Z-isomer),3.61(s,1.14H,Z-isomer),3.51(s,1.86H,E-isomer),2.34(s,3H),2.32(q,J＝7.5Hz,1.24H,E-isomer),2.15(q,J＝7.5Hz,0.76H,Z-isomer),1.72–1.65(m,1.24H,E-isomer),1.65–1.60(m,0.76H,Z-isomer),1.07(m,13.02H,E-isomer),and1.03(m,7.98H,Z-isomer).13C NMR(CDCl3,101MHz):155.56,154.99,137.77,137.56,133.67,133.34,129.15,128.73,128.62,125.95,113.60,99.82,63.31,63.04,58.62,55.07,34.68,33.40,24.00,22.12,21.39,21.29,18.20,18.16,12.21,and12.17.IR(thin film,cm-1):2941,2864,1742,1462,1102,1071,882,821,680,and 657cm-1.HRMS(DART-TOF)calculated for C22H38NaO2Si+[M+Na]+m/z 385.2533,found 385.2538.
(47) (R) -1- (1-methoxy-4, 8-dimethylnonyl-1, 7-dienyl) -4-methylbenzene (21d)
Figure BDA0002023477080000371
With reference to standard procedures, α -O-alkenylsulfone 19d (0.30mmol,97mg,1.0equiv), p-tolylboronic acid (0.60mmol,81.6mg,2.0equiv), Ni (COD) prepared in example 12(0.03mmol,8.25mg,0.1equiv),Cy3PHBF4A mixture of (0.06mmol,22.0mg,0.2equiv), and KOH (0.60mmol,33.6mg,2.0equiv) was stirred in tetrahydrofuran (1.5mL) at 60 ℃ for 8 hours. Column chromatography was performed with petroleum ether/ethyl acetate 25:1 as eluent to give compound 21d (65mg,0.24mmol, 78%) as a colorless oil.1H NMR(CDCl3,400MHz):7.36–7.31(m,1.5H),7.26–7.22(m,0.5H),7.17–7.11(m,2H),5.25(t,J＝7.2Hz,0.76H,E-isomer),5.15–5.09(m,0.76H,E-isomer),5.08–5.04(m,0.24H,Z-isomer),4.70(t,J＝7.2Hz,0.24H,Z-isomer),3.62(s,0.72H,Z-isomer),3.50(s,2.28H,E-isomer),2.35(s,3H),2.32–2.21(m,1H),2.18–2.08(m,1H),2.05–1.89(m,2H),1.68(s,3H),1.61(s,3H),1.55–1.45(m,1H),1.44–1.31(m,1H),1.26–1.14(m,1H),0.94(d,J＝6.6Hz,2.28H,E-isomer),and0.86(d,J＝6.7Hz,0.72H,Z-isomer).13C NMR(CDCl3,101MHz):155.81,155.28,137.71,137.55,133.85,133.44,131.20,131.17,129.15,128.79,128.72,126.01,125.10,125.08,112.65,98.86,58.47,55.10,37.04,36.75,34.58,34.26,33.33,32.76,25.87,25.85,25.75,21.41,21.30,19.86,19.61,17.79,and17.75.IR(thin film,cm-1):2956,2919,1275,1260,1075,822,764,and 750cm-1.HRMS(DART-TOF)calculated for C19H28NaO+[M+Na]+m/z295.2032,found 295.2033.
Example 4 preparation of ketones Using the open alkenyl ethers prepared according to the invention
The open alkenyl ether (compounds 21a to 21d) prepared in example 3 was dissolved in dichloromethane, cooled to 0 ℃ and trifluoroacetic acid (TFA, 10.0equiv) was added. Stirred for 2 hours. TLC detection reaction is completed, saturated sodium bicarbonate is quenched, dichloromethane is used for extraction, anhydrous sodium sulfate is used for drying, reduced pressure distillation and column chromatography separation are carried out, and the product ketone is obtained.
(1) 1-p-tolyl-2-acetophenone (22a)
Figure BDA0002023477080000372
Using the open alkenyl ether 21a prepared in example 3 (0.22mmol,49mg) and trifluoroacetic acid (2.2mmol,250mg), dissolved in dichloromethane (1.6mL) was stirred at room temperature for 2 hours, according to standard procedures. Column chromatography was performed using petroleum ether/ethyl acetate 15:1 as eluent to give compound 22a (23mg,0.13mmol, 50% yield) as a colorless oil.1H NMR(CDCl3,400MHz):7.95–7.86(m,2H),7.34–7.28(m,2H),7.28–7.20(m,5H),4.25(s,2H),and2.39(s,3H).13C NMR(CDCl3,101MHz):197.38,144.08,134.92,134.28,129.56,129.44,128.89,128.76,126.92,45.55,and21.76.IR(thin film,cm-1):3027,3005,2905,1682,1333,1275,1260,814,764,750,and 696cm-1.HRMS(DART-TOF)calculated forC15H14NaO+[M+Na]+m/z 233.0937,found 233.0944.
(2) 4-methyl-1-p-tolylpentanone (22b)
Figure BDA0002023477080000381
Preparation of the product of example 3 with reference to the Standard procedureThe prepared open alkenyl ether 21b (0.18mmol,37mg) and trifluoroacetic acid (1.8mmol,205mg) were dissolved in dichloromethane (1.6mL) and stirred at room temperature for 2 hours. Column chromatography was performed using petroleum ether/ethyl acetate 15:1 as eluent to give compound 22b (24mg,0.126mmol, 70% yield) as a colorless oil.1H NMR(CDCl3,400MHz):7.91–7.82(m,2H),7.28–7.21(m,2H),2.98–2.89(m,2H),2.40(s,3H),1.71–1.64(m,1H),1.64–1.59(m,2H),and0.94(d,J＝6.0Hz,6H).13C NMR(CDCl3,101MHz):199.55,142.68,133.76,128.35,127.32,35.66,32.53,27.03,21.58,and20.73.IR(thinfilm,cm-1):3005,2988,2956,1682,1275,1260,764,and 750cm-1.HRMS(DART-TOF)calculated for C13H18NaO+[M+Na]+m/z 2813.1250,found 213.1251.
(3) 5-hydroxy-1-p-tolylpentanone (22c)
Figure BDA0002023477080000382
Using alkenyl ether 21c (0.18mmol,65mg) prepared in example 3 and trifluoroacetic acid (1.8mmol,205mg), it was dissolved in dichloromethane (1.6mL) and stirred at room temperature for 2 hours, according to standard procedures. Distilling under reduced pressure, adding tetrahydrofuran solution of tetrabutylammonium fluoride (5mL, 1M), stirring at room temperature for 2 hr, quenching with saturated ammonium chloride solution, extracting with ethyl acetate, and extracting with anhydrous Na2SO4Drying and distilling under reduced pressure. Column chromatography was performed with petroleum ether/ethyl acetate 15:1 as eluent to give compound 22c as a colorless oil (73% yield over two steps).1H NMR(CDCl3,400MHz):7.89–7.82(m,2H),7.27–7.22(m,2H),3.67(t,J＝6.4Hz,2H),2.99(t,J＝7.1Hz,2H),2.41(s,3H),1.93(br s,1H),1.87–1.79(m,2H),and1.69–1.61(m,2H).13C NMR(CDCl3,101MHz):200.21,143.91,134.58,129.37,128.29,62.47,38.10,32.40,21.73,and20.41.IR(thin film,cm-1):3408,2931,2868,1674,1606,1449,1407,1275,1260,1229,1180,1057,1010,978,804,764,and 749cm-1.HRMS(DART-TOF)calculated for C12H16NaO2 +[M+Na]+m/z 215.1043,found 215.1029.
(4) (R) -4, 8-dimethyl-1-p-tolylnonyl-7-en-1-one (22d)
Figure BDA0002023477080000383
Using the open alkenyl ether 21d prepared in example 3 (0.108mmol,28mg) and trifluoroacetic acid (1.08mmol,123mg), dissolved in dichloromethane (1.6mL) and stirred at room temperature for 2h, according to standard procedures. Column chromatography was performed using petroleum ether/ethyl acetate 15:1 as eluent to give 22d (26mg,0.102mmol, 95% yield) as a colorless oil.1H NMR(CDCl3,400MHz):7.89–7.82(m,2H),7.28–7.23(m,2H),3.01–2.94(m,1H),2.94–2.86(m,1H),2.41(s,3H),1.86–1.72(m,3H),1.54(s,6H),1.52–1.47(m,1H),1.42–1.30(m,3H),1.25–1.14(m,1H),and0.93(d,J＝6.2Hz,3H).13C NMR(CDCl3,101MHz):200.43,143.79,134.73,129.39,128.31,89.43,40.69,37.01,36.27,32.53,31.53,25.70,21.75,21.22,and19.47.IR(thin film,cm-1):3004,2952,2871,1774,1681,1370,1275,1260,1214,1159,1137,764,and 750cm-1.HRMS(DART-TOF)calculated for C18H26NaO2 +[M+Na]+m/z281.1876,found 281.1881.
Example 5 preparation of diabetes drugs Using aryl glycoside prepared according to the present invention
The method becomes a new method for preparing the diabetes mellitus type II medicaments of the eggliflozin and the 2-deoxyeggliflozin, and comprises the following steps:
step 1:
Figure BDA0002023477080000391
1- (3- (benzo [ b ] thiophene-2-methyl) -4-fluorophenyl) -3,4, 6-tri-tert-butyldimethylsilyloxy-D-glucal (25)
With reference to the standard procedures, α -O alkenylsulfone 15a (0.30mmol,189mg,1.0equiv) prepared in example 1, borate 24(0.45mmol,166mg,1.5equiv), Ni (COD)2(0.03mmol,8.25mg,0.1equiv),Cy3PHBF4(0.06mmol,22.0mg,02equiv), and KOH (0.60mmol,33.6mg,2.0equiv) in tetrahydrofuran (1.5mL), stirring at 60 ℃ for 12 hours. Column chromatography (petroleum ether/ethyl acetate 8:1) gave product 25 as a white solid. (192mg,0.264mmol, 88%).1H NMR(CDCl3,400MHz):7.76–7.71(m,1H),7.68–7.63(m,1H),7.56(dd,J＝7.3,2.3Hz,1H),7.50(ddd,J＝8.6,5.0,2.3Hz,1H),7.32–7.28(m,1H),7.27–7.22(m,1H),7.04(t,J＝9.2Hz,1H),7.02(s,1H),5.17(d,J＝4.4Hz,1H),4.25(s,2H),4.17–4.14(m,1H),4.15–4.11(m,1H),3.98(dd,J＝11.2,6.9Hz,1H),3.88–3.85(m,1H),3.84(dd,J＝11.6,3.6Hz,1H),0.91–0.87(m,27H),0.12(s,6H),0.11(s,3H),0.10(s,3H)0.02(s,3H),and0.01(s,3H).13C NMR(CDCl3,101MHz):161.06(d,J＝248.0Hz),149.93,143.47,140.17,139.94,132.01(d,J＝3.5Hz),128.15(d,J＝4.3Hz),126.29(d,J＝16.2Hz),125.84(d,J＝8.2Hz),124.26,123.82,123.14,122.27,121.99,115.30(d,J＝22.4Hz),98.18,80.74,70.49,69.25,61.75,30.27(d,J＝3.3Hz),26.12,26.07,26.06,18.50,18.28,18.27,-3.83,-3.88,-3.97,-4.52,-5.11,and-5.16.19F NMR(CD3OD,376MHz):–118.19.IR(thin film,cm-1):2953,2929,2857,1726,1471,1275,1259,1102,835,764,and749cm-1.HRMS(DART-TOF)calculated for C39H63FNaO5SSi3 +[M+Na]+m/z 769.3580, found769.3582 melting point: 156.3-157.9 ℃.
Step 2:
Figure BDA0002023477080000392
compound 25(72.9mg,0.1mmol,1.0equiv) was dissolved in THF (2mL), cooled to 0 deg.C, and BH was added slowly3THF (1.0M,0.3mL,0.3mmol,3.0equiv), stir for 12 hours. Adding 30% of H2O2A further 3M aqueous NaOH solution (3.0mL) was added (3.0 mL). Stirred at room temperature for 24 hours. Dilute with dichloromethane (25mL), followed by 20% NaHSO3(25mL), saturated NH4Cl (25mL), water (25mL), and saturated brine (25 mL). Anhydrous Na for organic layer2SO4Drying, filtering and distilling under reduced pressure. The crude product was dissolved in THF (2mL) and tetra-chargedButylammonium fluoride (TBAF, 1.0M in THF,0.33mL,3.3eq.), was stirred at room temperature for 2 hours. Concentration and column chromatography (DCM/MeOH 20:1) gave eprogliflozin 26a (19.8mg, 49% for the same steps) as a white solid.1H NMR(CD3OD,400MHz):7.72(d,J＝7.9Hz,1H),7.64(d,J＝7.7Hz,1H),7.42(dd,J＝7.4,2.2Hz,1H),7.35(ddd,J＝7.7,5.1,2.2Hz,1H),7.27(t,J＝7.4Hz,1H),7.25–7.18(m,1H),7.09(d,J＝9.2Hz,1H),7.05(d,J＝4.7Hz,1H),4.31–4.19(m,2H),4.11(d,J＝9.4Hz,1H),3.91–3.82(m,1H),3.68(dd,J＝12.0,4.7Hz,1H),and3.49–3.32(m,4H).13C NMR(CD3OD,101MHz):162.28(d,J＝245.0Hz),145.47,141.99,141.61,137.73(d,J＝3.5Hz),132.28(d,J＝4.4Hz),129.84(d,J＝8.2Hz),127.94(d,J＝16.0Hz),125.70,125.27,124.49,123.46,123.35,116.39(d,J＝22.4Hz),83.35,82.70,80.26,77.01,72.38,63.60,and31.19(d,J＝3.4Hz).19F NMR(CD3OD,376MHz):–121.56.IR(thin film,cm-1):3361,2925,1501,1457,1275,1260,1086,764,and 750cm-1.HRMS(DART-TOF)calculated for C21H21FNaO5S+[M+Na]+m/z 427.0986, found 427.0984, m/z melting point 146.2-147.9 ℃.
And step 3:
Figure BDA0002023477080000401
compound 25(72.9mg,0.1mmol,1.0eq.) was dissolved in a mixed solvent, AcOEt/MeOH (5:1,36mL), 10% Pd/C (150mg) was added, and the mixture was stirred under hydrogen atmosphere for 24 hours. Filtering with diatomite, and distilling under reduced pressure. The crude product was dissolved in THF (2mL) and tetrabutylammonium fluoride (TBAF, 1.0M in THF,0.33mL,3.3eq.) was added. Stirring was carried out at room temperature for 2 hours, distillation under reduced pressure and column chromatography (DCM/MeOH 20:1) gave 2-deoxyegelizin 26b (33.1mg, 85% for two steps) as a white solid.1H NMR(CD3OD,400MHz):7.71(d,J＝7.8Hz,1H),7.64(d,J＝7.6Hz,1H),7.39(d,J＝7.2Hz,1H),7.37–7.30(m,1H),7.30–7.17(m,2H),7.12–7.04(m,1H),7.02(s,1H),4.48(d,J＝11.4Hz,1H),4.24(s,2H),3.90(d,J＝11.6Hz,1H),3.79–3.62(m,2H),3.38–3.21(m,2H),2.14(d,J＝12.9Hz,1H),and1.68–1.50(m,1H).13C NMR(CD3OD,101MHz):161.95(d,J＝244.7Hz),145.51,141.93,141.56,139.96(d,J＝3.6Hz),130.48(d,J＝4.3Hz),128.23(d,J＝5.5Hz),128.11(d,J＝2.3Hz),125.72,125.29,124.49,123.47,123.28,116.58(d,J＝22.4Hz),82.66,78.49,74.53,73.74,63.74,43.25,and31.20(d,J＝3.3Hz).19F NMR(CD3OD,376MHz):–121.95.IR(thin film,cm-1):3348,2921,2847,1501,1275,1260,1064,1026,824,764,and 749cm-1.HRMS(DART-TOF)calculated forC21H21FNaO4S+[M+Na]+m/z 411.1037,found 411.1042.
Example 6 preparation of diabetes drugs Using aryl glycoside prepared according to the present invention
Figure BDA0002023477080000402
1- (3- (benzo [ b ] thiophene-2-methyl) -4-fluorophenyl) -3-O-triisopropylsiloxy-4, 6-O-di-tert-butylsilyl-D-glucal ene
With reference to the standard procedures, α -O alkenylsulfone 15b (0.30mmol,175mg,1.0equiv) prepared in example 1, borate 24(0.45mmol,166mg,1.5equiv), Ni (COD)2(0.03mmol,8.25mg,0.1equiv),Cy3PHBF4(0.06mmol,22.0mg,0.2equiv), and KOH (0.60mmol,33.6mg,2.0equiv) in tetrahydrofuran (1.5mL) were stirred at 60 ℃ for 12 hours. Column chromatography (petroleum ether/ethyl acetate 8:1) gave product 27. (102mg,0.15mmol, 50%).1H NMR(CDCl3,400MHz):7.76–7.70(m,1H),7.65–7.63(m,1H),7.35–7.43(m,2H)，7.31–7.22(m,2H)，7.02(t,J＝9.6Hz,1H),7.00(s,1H),5.12(d,J＝2.3Hz,1H),4.54(dd,J＝2.3,6.8Hz,1H),4.30–4.25(m,1H),4.23(s,2H),4.10–4.05(m,2H),3.99–3.92(m,1H),1.17–1.08(m,21H),1.07(s,9H),and1.00(s,9H).IR(thin film,cm-1):2943,2860,1726,1471,1276,1259,1152,828,762,and 750cm-1.HRMS(DART-TOF)calculated forC38H55FNaO4SSi2 +[M+Na]+m/z 682.3344,found 682.3340。
Figure BDA0002023477080000411
Compound 27(68.3mg,0.1mmol,1.0equiv) was dissolved in THF (2mL), cooled to 0 deg.C, and BH was added slowly3THF (1.0M,0.3mL,0.3mmol,3.0equiv), stir for 12 hours. Adding 30% of H2O2A further 3M aqueous NaOH solution (3.0mL) was added (3.0 mL). Stirred at room temperature for 24 hours. Dilute with dichloromethane (25mL), followed by 20% NaHSO3(25mL), saturated NH4Cl (25mL), water (25mL), and saturated brine (25 mL). Anhydrous Na for organic layer2SO4Drying, filtering and distilling under reduced pressure. The crude product was dissolved in THF (2mL), tetrabutylammonium fluoride (TBAF, 1.0M in THF,0.33mL,3.3eq.) was added, and stirred at room temperature for 2 hours. Concentration and column chromatography (DCM/MeOH 20:1) gave eprogliflozin 26a (18.2mg, 45% for the same steps) as a white solid.1H NMR(CD3OD,400MHz):7.72(d,J＝7.9Hz,1H),7.64(d,J＝7.7Hz,1H),7.42(dd,J＝7.4,2.2Hz,1H),7.35(ddd,J＝7.7,5.1,2.2Hz,1H),7.27(t,J＝7.4Hz,1H),7.25–7.18(m,1H),7.09(d,J＝9.2Hz,1H),7.05(d,J＝4.7Hz,1H),4.31–4.19(m,2H),4.11(d,J＝9.4Hz,1H),3.91–3.82(m,1H),3.68(dd,J＝12.0,4.7Hz,1H),and3.49–3.32(m,4H).13C NMR(CD3OD,101MHz):162.28(d,J＝245.0Hz),145.47,141.99,141.61,137.73(d,J＝3.5Hz),132.28(d,J＝4.4Hz),129.84(d,J＝8.2Hz),127.94(d,J＝16.0Hz),125.70,125.27,124.49,123.46,123.35,116.39(d,J＝22.4Hz),83.35,82.70,80.26,77.01,72.38,63.60,and31.19(d,J＝3.4Hz).19F NMR(CD3OD,376MHz):–121.56.IR(thin film,cm-1):3361,2925,1501,1457,1275,1260,1086,764,and 750cm-1.HRMS(DART-TOF)calculated for C21H21FNaO5S+[M+Na]+m/z 427.0986, found 427.0984, m/z melting point 146.2-147.9 ℃.
And step 3:
Figure BDA0002023477080000412
compound 27(68.3mg,0.1mmol,1.0eq.) was dissolved in a mixed solvent, AcOEt/MeOH (5:1,36mL),10% Pd/C (150mg) was added, and the mixture was stirred under hydrogen atmosphere for 24 hours. Filtering with diatomite, and distilling under reduced pressure. The crude product was dissolved in THF (2mL) and tetrabutylammonium fluoride (TBAF, 1.0M in THF,0.33mL,3.3eq.) was added. Stirring was carried out at room temperature for 2 hours, distillation under reduced pressure and column chromatography (DCM/MeOH 20:1) gave 2-deoxyegelizin 26b (31.1mg, 80% for two steps) as a white solid.1H NMR(CD3OD,400MHz):7.71(d,J＝7.8Hz,1H),7.64(d,J＝7.6Hz,1H),7.39(d,J＝7.2Hz,1H),7.37–7.30(m,1H),7.30–7.17(m,2H),7.12–7.04(m,1H),7.02(s,1H),4.48(d,J＝11.4Hz,1H),4.24(s,2H),3.90(d,J＝11.6Hz,1H),3.79–3.62(m,2H),3.38–3.21(m,2H),2.14(d,J＝12.9Hz,1H),and1.68–1.50(m,1H).13C NMR(CD3OD,101MHz):161.95(d,J＝244.7Hz),145.51,141.93,141.56,139.96(d,J＝3.6Hz),130.48(d,J＝4.3Hz),128.23(d,J＝5.5Hz),128.11(d,J＝2.3Hz),125.72,125.29,124.49,123.47,123.28,116.58(d,J＝22.4Hz),82.66,78.49,74.53,73.74,63.74,43.25,and31.20(d,J＝3.3Hz).19F NMR(CD3OD,376MHz):–121.95.IR(thin film,cm-1):3348,2921,2847,1501,1275,1260,1064,1026,824,764,and 749cm-1.HRMS(DART-TOF)calculated forC21H21FNaO4S+[M+Na]+m/z 411.1037,found 411.1042.
In conclusion, when the alpha-O-alkenyl sulfone is used as the electrophilic reagent to carry out the Suzuki-Miyaura coupling reaction, the reaction raw material alpha-O-alkenyl sulfone has simple preparation and stable structure, and can overcome the defects of instability, difficult preparation and the like when the organic halide and the sulfonic acid are used as the electrophilic reagent of the Suzuki-Miyaura coupling reaction. Meanwhile, the reaction conditions of the reaction are mild, the heterocyclic ring and various functional groups can be compatible, the yield is high, and the large-scale process production can be realized. Meanwhile, the invention utilizes alpha-O-alkenyl sulfone as an electrophilic reagent to carry out Suzuki-Miyaura coupling reaction, can generate aryl glycoside and open-chain alkenyl ether with high yield, can also prepare type II diabetes drugs of eggliflozin and 2-deoxyeggliflozin, and has wide application.

Claims (11)

1. A preparation method of a medicine of eggliflozin for treating diabetes or a derivative thereof is characterized in that: it comprises the following steps:
(1) reacting alpha-O-alkenyl sulfone, an organic boron reagent, a ligand, alkali and a catalyst in a solvent to obtain a compound I;
(2) reducing and substituting the compound I to obtain a coarse product of the epropanal; or the compound I is reduced to obtain a crude product of the epropanal derivative;
(3) purifying the crude product of the eprost or the crude product of the eprost derivative to obtain the eprost or the eprost derivative;
wherein the structural formula of the alpha-O-alkenyl sulfone is shown as a formula II:
Figure FDA0002023477070000011
in the formula II, the reaction mixture is shown in the formula II,
n is an integer of 0 to 4;
R1independently selected from substituted or unsubstituted C1～C6Alkyl, -OR3Or any two R1Connecting to form a substituted or unsubstituted 3-to 6-membered heterocyclic group; the substituent of the alkyl is halogen, nitryl, amino, hydroxyl, cyano-OR3(ii) a The substituent of the heterocyclic group is C1～C6An alkyl group;
R2selected from substituted or unsubstituted aryl, substituted or unsubstituted 3-8 membered heterocyclic group; the substituent of the aryl or the heterocyclic group is C1～C6Alkyl, halogen, C1～C6Alkoxy, cyano, nitro, amino, hydroxy;
R3selected from benzyl, TBS group, TIPS group, substituted or unsubstituted 3-6 member heterocyclic group; the substituent of the heterocyclic group is substituted or unsubstituted C1～C6Alkyl, -OR4(ii) a The substituent of the alkyl is halogen, hydroxyl, -OR4；
R4Selected from benzyl, TBS groups, TIPS groups;
the organoboron reagent is
Figure FDA0002023477070000012
The structural formula of the compound I is
Figure FDA0002023477070000013
In the compound I, the reaction mixture is subjected to reaction,
n and R1The same as the alpha-O-alkenyl sulfone shown in the formula II.
2. The method of claim 1, wherein: in the step (1), the molar ratio of the alpha-O-alkenyl sulfone to the organoboron reagent to the ligand to the base to the catalyst in the coupling reaction is 1: 1-5: 0.1-0.5: 1-5: 0.05-0.25; the molar volume ratio of the alpha-O-alkenyl sulfone to the solvent is 0.1-10: 1 (mol/L);
preferably, the mol ratio of the alpha-O-alkenyl sulfone to the organoboron reagent to the ligand to the base to the catalyst in the coupling reaction is 1: 1.5-2: 0.1-0.2: 2: 0.1; the molar volume ratio of the alpha-O-alkenyl sulfone to the solvent is 0.1-0.. 2:1 (mol/L);
more preferably, the molar ratio of the alpha-O-alkenyl sulfone, the organoboron reagent, the ligand, the base and the catalyst in the coupling reaction is 1:2:0.2:2: 0.1; the molar volume ratio of the alpha-O-alkenyl sulfone to the solvent is 0.2:1 (mol/L).
3. The method of claim 1, wherein:
in the formula II, the reaction mixture is shown in the formula II,
n is an integer of 2-3;
R1independently selected from substituted OR unsubstituted methyl, -OR3Or any two R1To form a substituted 6-membered heterocyclic group; the substituent of the methyl is-OR3(ii) a The substituent of the heterocyclic group is C4An alkyl group;
R2selected from substituted or unsubstituted aryl, substituted or unsubstituted 6-membered heterocyclyl; the substituent of the aryl or the heterocyclic group is C1～C3Alkyl, halogen;
R3selected from benzyl, TBS groups, TIPS groups, substituted 6-membered heterocyclic groups; the substituent of the heterocyclic group is substituted methyl alkyl, -OR4(ii) a The substituent of the alkyl is-OR4；
R4Is selected from benzyl;
preferably, the α -O-alkenyl sulfone is of one of the following structural formulae:
Figure FDA0002023477070000021
more preferably, the α -O-alkenyl sulfone is of one of the following structural formulae:
Figure FDA0002023477070000022
4. the production method according to claim 1 or 2, characterized in that: in step (1), the ligand is selected from Ph3P or Cy3P·HBF4(ii) a The alkali is selected from KOH or NaOH; the catalyst is a Ni-containing catalyst; the solvent is tetrahydrofuran or tert-butyl alcohol;
preferably, in step (1), the ligand is Cy3P·HBF4(ii) a The alkali is KOH; the catalyst is Ni (COD)2(ii) a The solvent is tetrahydrofuran.
5. The production method according to claim 1 or 2, characterized in that: in the step (1), the reaction temperature is 60-80 ℃; the reaction time is 8-16 h; preferably, the reaction time is 12-16 h.
6. The method of claim 1, wherein: in the step (2), the compound I is reduced and substituted to obtain a crude product of the israzin, wherein the compound I is reduced to be dissolved in a solvent, cooled to 0 ℃, slowly added with a reducing agent and stirred for 10-15 hours; the substitution is that 3% H is added into the reduced product2O2Then adding 3M NaOH aqueous solution, and stirring at room temperature for 20-25 h to obtain the aqueous solution; after the substitution, purifying the substituted product;
wherein the molar ratio of the compound I to the reducing agent is 1-5; the molar volume ratio of the compound I to the solvent is 0.1: 1-5 (mol/L); compound I and 3% H2O2The molar volume ratio of (a) is 0.1: 1-5 (mol/L); the molar volume ratio of the compound I to the NaOH aqueous solution is 0.1: 1-5 (mol/L);
preferably, in the step (2), the molar ratio of the compound I to the reducing agent is 1-3; the molar volume ratio of the compound I to the solvent is 0.1:2 (mol/L); compound I and 3% H2O2The molar volume ratio of (a) to (b) is 0.1:3 (mol/L); the molar volume ratio of the compound I to the aqueous NaOH solution was 0.1:3 (mol/L).
7. The method of claim 6, wherein: in the step (2), the compound I is reduced and substituted to obtain the ipragliflozin, the reduced compound I is dissolved in tetrahydrofuran, the temperature is cooled to 0 ℃, borane-tetrahydrofuran is slowly added, and the mixture is stirred for 12 hours; the substitution is that 30% H is added into the reduced product2O2Then adding 3M NaOH aqueous solution, and stirring at room temperature for 24 h; diluting the substituted product with dichloromethane, washing, drying an organic layer, filtering, and distilling under reduced pressure to obtain the product after purification;
preferably, in step (2), the purification is performed by diluting the substituted product with dichloromethane, and then sequentially using 20% NaHSO3Saturated NH4Washing with Cl, water and saturated brine, and washing the organic layer with anhydrous Na2SO4Drying, filtering, and distilling under reduced pressure.
8. The method of claim 1, wherein: in the step (2), reducing the compound I to obtain a coarse product of the ipragliflozin derivative, dissolving the reduced compound I in a solvent, and stirring and reacting the reduced compound I in a hydrogen environment for 20-30 hours under the action of a catalyst; after the reduction, purifying the reduced product;
wherein the mass-volume ratio of the compound I to the solvent is 1: 500-550 (w/v); the mass ratio of the compound I to the catalyst is 1: 0.2-0.6;
preferably, in the step (2), the mass-to-volume ratio of the compound I to the solvent is 1: 527-528 (w/v); the mass ratio of the compound I to the catalyst is 1: 0.4-0.5.
9. The method of claim 8, wherein: in the step (2), the solvent consists of ethyl acetate and methanol in a volume ratio of 5: 1; the catalyst is 10% Pd/C; the stirring reaction time is 24 hours; the purification is carried out by filtering with diatomite and reduced pressure distillation.
10. The method of claim 1, wherein: and (3) dissolving the crude product in tetrahydrofuran, adding tetrabutylammonium fluoride, stirring at room temperature for 2 hours, carrying out reduced pressure distillation, and carrying out column chromatography separation.
11. The method of claim 1, wherein: the structural formula of the eprost or the eprost derivative is shown as a formula III:
Figure FDA0002023477070000031
preferably, the structure formula of the epropane or the epropane derivative is shown as the formula IIIA:
Figure FDA0002023477070000032
more preferably, the structure of the eprogliflozin or eproflozin derivative is as follows:
Figure FDA0002023477070000033
CN201910287224.8A 2019-04-10 2019-04-10 Preparation method of drug eprogliflozin for treating diabetes or derivative thereof Active CN111808089B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910287224.8A CN111808089B (en) 2019-04-10 2019-04-10 Preparation method of drug eprogliflozin for treating diabetes or derivative thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910287224.8A CN111808089B (en) 2019-04-10 2019-04-10 Preparation method of drug eprogliflozin for treating diabetes or derivative thereof

Publications (2)

Publication Number Publication Date
CN111808089A true CN111808089A (en) 2020-10-23
CN111808089B CN111808089B (en) 2023-04-11

Family

ID=72844164

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910287224.8A Active CN111808089B (en) 2019-04-10 2019-04-10 Preparation method of drug eprogliflozin for treating diabetes or derivative thereof

Country Status (1)

Country Link
CN (1) CN111808089B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105469A (en) * 2008-06-04 2011-06-22 阿斯利康(瑞典)有限公司 Heterocyclic urea derivatives for the treatment of bacterial infections
WO2015000412A1 (en) * 2013-07-02 2015-01-08 四川海思科制药有限公司 Benzocyclobutene derivative and preparation method and pharmaceutical application thereof
CN105294785A (en) * 2014-07-02 2016-02-03 上海阳帆医药科技有限公司 C-benzo five-membered heteroaromatic aryl glucoside derivative as well as preparation method and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105469A (en) * 2008-06-04 2011-06-22 阿斯利康(瑞典)有限公司 Heterocyclic urea derivatives for the treatment of bacterial infections
WO2015000412A1 (en) * 2013-07-02 2015-01-08 四川海思科制药有限公司 Benzocyclobutene derivative and preparation method and pharmaceutical application thereof
CN104507921A (en) * 2013-07-02 2015-04-08 四川海思科制药有限公司 Benzocyclobutene derivative and preparation method and pharmaceutical application thereof
CN105294785A (en) * 2014-07-02 2016-02-03 上海阳帆医药科技有限公司 C-benzo five-membered heteroaromatic aryl glucoside derivative as well as preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIANG GONG,等: "Ni-Catalyzed Suzuki–Miyaura Cross-Coupling of α-Oxo-vinylsulfones To Prepare C-Aryl Glycals and Acyclic Vinyl Ethers" *
张亦琳,等: "Ni催化的Suzuki偶联反应" *

Also Published As

Publication number Publication date
CN111808089B (en) 2023-04-11

Similar Documents

Publication Publication Date Title
CN108137526A (en) For producing the method for cannabidiol and △ -9- tetrahydrocannabinol
McAtee et al. The first example of nickel-catalyzed silyl-Heck reactions: direct activation of silyl triflates without iodide additives
Matsuzawa et al. One-step synthesis of benzo [b] thiophenes by aryne reaction with alkynyl sulfides
AU2004228159A1 (en) Process for preparation of cyclosporin "A" analogues having a terminal diene group
WO2017140274A1 (en) Tricyclic compound serving as immunomodulator
CN114085217A (en) Axial chiral pyridine biaryl ring compound and preparation method thereof
CN111808089B (en) Preparation method of drug eprogliflozin for treating diabetes or derivative thereof
CN109438317A (en) A kind of preparation method of nitrogen-alkyl (deuteroalkyl) heteroaromatic and alkyl (deuteroalkyl) aryl ethers compounds
Asgari et al. Aryne cycloaddition reactions of benzodioxasilines as aryne precursors generated by catalytic reductive ortho-CH silylation of phenols with traceless acetal directing groups
CN111808057B (en) Suzuki reaction using alpha-O-alkenyl sulfone as electrophile and application thereof
CN102153501B (en) Chiral nitrogen-containing heterocyclic compound, and synthesis method and application thereof
CN111171068B (en) Preparation method of silicon spiro-compound
Lipshutz et al. Nickel (0)-catalyzed couplings of vinyl-alanes &-zirconocenes with chloromethylated heteroaromatics: A route to E-allylated heterocycles
CN108164493B (en) Aromatic polyketone compound and preparation method thereof
CN101316813A (en) Method for producing vitamin D derivative by using convergent method
CN108341739B (en) Preparation method of alpha-aryl, heteroaryl or alkenyl-alpha, alpha-difluoromethyl compound
CN110698322B (en) Synthesis method of coastal twinborn anthane diterpene Stemarin
CN113024592A (en) Synthetic method of azetidine silicon precursor compound and method for synthesizing six-membered silicon nitrogen heterocyclic compound by using same
JPH0641114A (en) New mevalonolactones and its production
CN107151252B (en) A kind of preparation method for the piperidines cyclics that the fluoroalkyl of chirality replaces
CN108101879B (en) Polycyclic lactone compound and preparation method thereof
CN110330456B (en) Synthetic method of 2,2, 2-trifluoroethyl substituted phenanthridine compound
CN108047186B (en) Method for synthesizing benastatin G
CN108250173B (en) Method for synthesizing benastatin J
CN108276266B (en) Anthracycline compound and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant